Human proteins responsible for NEDD8 activation and conjugation

ABSTRACT

The invention relates to covalent modification of proteins through their conjugation with other proteins. More particularly, the invention relates to the modulation of such conjugation involving the protein NEDD8. The invention provides compositions and methods for detecting and/or modulating the activation and/or conjugation of NEDD8, as well as compositions and methods for discovering molecules which are useful in detecting and/or modulating the activation and/or conjugation of NEDD8. The present invention arises from the purification and characterization of novel NEDD8 activating and conjugating enzymes.

This application is a continuation-in-part of provisional applicationSer. No. 60/068,029, filed Dec. 19, 1997, and a continuation-in-part ofprovisional application Ser. No. 60/096,525, filed Aug. 12, 1998.

This invention was supported in part by grant number GM53136 fromNational Institute of Health. The government has certain rights in thisinvention.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The invention relates to covalent modification of proteins through theirconjugation with other proteins. More particularly, the inventionrelates to the modulation of such conjugation involving the proteinNEDD8.

2. Summary of the Related Art

Covalent modification of proteins through their conjugation with otherproteins is an important biological mechanism for regulating proteinmetabolism and biological activity. Hershko and Ciechanover, Annu. Rev.Biochem. 61: 761-807 (1992) discloses conjugation of ubiquitin, one ofthe most conserved eukaryotic proteins, to other proteins through anenzymatic mechanism, as well as its role in protein degradation. Rock etal., Cell 78: 761-771 (1994) discloses that ubiquitination of proteinantigens is required for processing of such antigens. Murray, Cell 81:149-152 (1995), teaches that ubiquitination of cyclin is involved incell cycle regulation. Scheffner et al., Cell 75: 495-505 (1993)discloses that ubiquitination of p53 is involved in degradation of thistumor suppressor.

The enzymatic pathway for ubiquitination has been reasonably welldefined jentsch, Annu. Rev. Genet. 26: 179-207 (1992) discloses thatubiquitination requires initial activation of a conserved C-terminalglycine residue by the ubiquitin activating enzyme, E1, throughformation of ubiquitin adenylate in an ATP-dependent process whichliberates PPi, followed by thiol ester formation at a thiol site in E1with release of AMP. Ubiquitin is then transferred to a thiol site inubiquitin conjugating enzyme, E2, through formation of a thiol esterbond. Ubiquitin is then transferred to an epsilon amino group of alysine residue in the target protein through an amide linkage, usuallywith the involvement ofubiquitin-protein isopeptide ligase, E3. HopkinJ. Natl. Inst. Health Res. 9: 36-42 (1997), teaches that targetspecificity is regulated by the particular combination of E2 and E3protein with more than 30 E2 proteins and 10 E3 proteins being known atpresent.

Ubiquitin is not the only protein which is used to modify other proteinsthrough covalent linkage, however. Kamitani et al., J. Biol. Chem. 272:14001-14004 (1997), discloses the sentrin, a ubiquitin-like protein,appears to be processed similarly to ubiquitin, but has a smaller targetprotein repertoire than ubiquitin. Okura et al., J. Immunol. 272:4277-4281 (1986) teaches that sentrin protects cells against anti-FASand tumor necrosis factor-mediated cell death. Loeb and Haas, J. Biol.Chem. 267: 7806-7813 (1982), discloses that ubiquitin cross-reactiveprotein (UCRP), which contains two ubiquitin domains, is conjugated to alarge number of intracellular proteins. Kumar et al., Biochem. Biophys.Res. Commun. 185: 1155-1161 (1992), discloses another ubiquitin-likeprotein, called NEDD8, for Neural precursor cell-ExpressedDevelopmentally Down regulated. Kamitani et al., J. Biol. Chem. 272:28557-28562 (1997), teaches that NEDD8 is predominantly expressed in thenucleus and is conjugated to target proteins through a mechanismanalogous to ubiquitination.

These proteins, which covalently modify other cellular proteins, areimportant components of biological regulatory processes. The nuclearexpression pattern and developmental regulation of NEDD8 make it aparticularly compelling candidate as an important regulatory molecule.There is a need, therefore to understand the role of NEDD8 in biologicalregulation. Unfortunately, the lack of understanding about the specificproteins involved in NEDD8 conjugation has resulted in a lack ofeffective tools to probe the role of NEDD8. There is, therefore, a needfor better tools to utilize in elucidating the role of NEDD8 inbiological regulation. Ideally, such tools would allow modulation of theactivation and/or conjugation of NEDD8.

BRIEF SUMMARY OF THE INVENTION

The invention provides compositions and methods for detecting and/ormodulating the conjugation of NEDD8 and/or its transfer to a targetprotein, as well as compositions and methods for discovering moleculeswhich are useful in detecting and/or modulating the conjugation of NEDD8and/or its transfer to a target protein. The present invention arisesfrom the purification and characterization of novel NEDD8 activating andconjugating enzymes.

In a first aspect, the invention provides purified NEDD8-activatingprotein beta subunit (NAE1-beta). The primary amino acid sequence of apreferred embodiment of such NAE1-beta protein is shown in FIG. 1.

A second aspect, the invention provides NAE1-beta expression elementsSuch elements include, without limitation, isolated of recombinantnucleic acid sequences encoding NAE1-beta or nucleic acid sequencesspecifically homologous or specifically complementary thereto, vectorscomprising any such nucleic acid sequences and recombinant expressionunits which express NAE1-beta, or, antisense transcripts or dominantnegative mutants thereof.

The purified protein and its structural information provided hereinenables the preparation of NAE1-beta-binding molecules (NAE1BBMs). Thus,in a third aspect, the invention provides methods for identifyingNAE1BBMs. One preferred method according to this aspect of the inventioncomprises screening for NAE1BBMs by contacting purified NAE1-betaaccording to the invention and populations of molecules or mixedpopulations of molecules and determining the presence of molecules whichbind specifically to NAE1-beta. Another preferred method according tothis aspect of the invention comprises rationally designing molecules tobind NAE1-beta based upon structural information from the purifiedNAE1-beta protein provided by the invention and determining whether suchrationally designed molecules bind specifically to NAE1-beta. Thisaspect of the invention includes NAE1BBMs identified by the methodsaccording to the invention.

NAE1BBMs can be used in conventional assays to detect the presence orabsence, and/or quantity of NAE1-beta, NAE1 heterodimer, or NAE1heterodimer/NEDD8 complex in a biological sample. Thus, in a fourthaspect, the invention provides methods for determining the presence orabsence and/or quantity of NAE1-beta, NAE1 heterodimer, or NAE1heterodimer/NEDD8 complex in a biological sample. Such methods compriseproviding a detectable NAE1BBM to a biological sample, allowing thedetectable NAE1BBM to bind to NAE1-beta, NAE1 heterodimer, or NAE1heterodimer/NEDD8 complex, if any is present in the biological sample,and detecting the presence or absence and/or quantity of a complex ofthe detectable NAE1BBM and NAE1-beta, NAE1-heterodimer, or NAE1heterodimer/NEDD8 complex.

Nucleic acid sequences specifically complementary to and/or specificallyhomologous to nucleic acid sequences encoding NAE1-beta can also be usedin conventional assays to detect the presence or absence of NAE1-betanucleic acid in a biological sample. Thus, in a fifth aspect, theinvention provides methods for determining the presence or absenceand/or quantity of NAE1-beta nucleic acid in a biological sample. Inpreferred embodiments, such assays are nucleic acid hybridization and/oramplification assay, such assays comprising providing to the biologicalsample a nucleic acid sequence which is specifically complementary toNAE1-beta nucleic acid.

In a sixth aspect, the invention provides methods for identifyingmodulating ligands of NAE1-beta. Some NAE1BBMs are capable of acting asantagonists or agonists of NAE1-beta. Thus, the method according to thisaspect of the invention comprises providing NAE1BBMs to an assay systemfor NAE1-beta participation in the NEDD8-activation/conjugation pathway,and determining whether such NAE1BBMs interfere with or enhance theability of NAE1-beta to participate in the NEDD8-activation/conjugationpathway. The NAE1BBMs are preferably provided as a population ofmolecules (most preferably rationally designed molecules), or as a mixedpopulation of molecules, as for example in a screening procedure. Thisaspect of the invention includes modulating ligands of NAE1-betaidentified by this method according to the invention.

In a seventh aspect, the invention provides modulating ligands ofNAE1-beta. Preferred modulating ligands are NAE1BBMs which act asantagonists, interfering with the ability of NAE1-beta to participate inthe NEDD8-activation/conjugation pathway. Other preferred modulatingligands are NAE1BBMs which act as agonists, enhancing the ability ofNAE1-beta to participate in the NEDD8-activation/conjugation pathway. Incertain embodiments, such NAE1BBMs preferably interact with NAE1-beta toinhibit or enhance the formation of NAE1 heterodimer, the formation ofNEDD8 adenylate, the formation of a thiol ester bond between NEDD8 andNAE1, and/or transfer of NEDD8 to NEDD8-conjugating enzyme.

In an eighth aspect, the invention provides methods for modulating theactivation and/or conjugation of NEDD8. One preferred embodiment of themethod according to this aspect of the invention comprises providing amodulating ligand of NAE1-beta or a recombinant expression unit whichexpresses NAE1-beta or an antagonist thereof to a biological system inwhich NEDD8 is conjugated to another protein.

In a ninth aspect, the invention provides oligonucleotides that arespecifically complementary to a portion of a nucleotide sequence shownin FIG. 1. Preferred embodiments include hybridization probes andantisense oligonucleotides.

In a tenth aspect, the invention provides methods for identifyingNAE1-alpha binding molecules (NAE1ABMs). The present inventors haveidentified the alpha subunit of the NAE1 heterodimer (NAE1-alpha).Surprisingly, it has an amino acid sequence which is substantiallyidentical to a protein previously identified as amyloid precursorprotein binding protein 1 (APP-BP1; see Chow et al., J. Biol. Chem. 271:11339-11346 (1996)). One preferred method according to this aspect ofthe invention comprises screening for NAE1ABMs by contacting purifiedNAE1-alpha and populations of molecules or mixed populations ofmolecules and determining the presence of molecules which bindspecifically to NAE1-alpha. Another preferred method according to thisaspect of the invention comprises rationally designing molecules to bindNAE1-alpha based upon structural information from the NAE1-alpha proteinidentified by the present inventors and determining whether suchrationally designed molecules bind specifically to NAE1-alpha. Thisaspect of the invention includes NAE1ABMs identified by the methodsaccording to the invention.

NAE1ABMs cn be used in conventional assays to detect the presence orabsence, and/or quantity of NAE1-alpha, NAE1 heterodimer, or NAE1heterodimer/NEDD8 complex in a biological sample. Thus, in an eleventhaspect, the invention provides methods for determining the presence ofabsence and/or quantity of NAE1-alpha, NAE1 heterodimer, or NAE1heterodimer/NEDD8 complex in a biological sample. Such methods compriseproviding a detectable NAE1ABM to a biological sample, allowing thedetectable NAE1ABM to bind to NAE1-alpha, NAE1 heterodimer, or NAE1heterodimer/NEDD8 complex, if any is present in the biological sample,and detecting the presence or absence and/or quantity of a complex ofthe detectable NAE1ABM and NAE1-alpha, NAE1-heterodimer, or NAE1heterodimer/NEDD8 complex. In preferred embodiments, the methodaccording to this aspect of the invention is used to detect the presenceor absence, and/or quantity of NAE1 heterodimer or NAE1heterodimer/NEDD8 complex in a biological sample.

Nucleic acid sequences specifically complementary to and/or specificallyhomologous to nucleic acid sequences encoding NAE1-alpha can also beused in conventional assays to detect the presence or absence ofNAE1-alpha nucleic acid in a biological sample in which NEDD8conjugation is suspected. Thus, in a twelfth aspect, the inventionprovides methods for determining the presence or absence and/or quantityof NAE1-alpha nucleic acid in such a biological sample. In preferredembodiments, such assays are nucleic acid hybridization and/oramplification assays, such assays comprising providing to the biologicalsample a nucleic acid sequence which is specifically complementary toNAE1-alpha nucleic acid.

In an thirteenth aspect, the invention provides methods for identifyingmodulating ligands of NAE1-alpha. Some NAE1ABMs are capable of acting asantagonists or agonists of NAE1-alpha. Thus, the method according tothis aspect of the invention comprises providing NAE1ABMs to an assaysystem for NAE1-alpha participation in the NEDD8-activation/conjugationpathway, and determining whether such NAE1ABMs interfere with or enhancethe ability of NAE1-alpha to participate in theNEDD8-activation/conjugation pathway. The NAE1ABMs are preferablyprovided as a population of molecules (most preferably rationallydesigned molecules), or as a mixed population of molecules, as forexample in a screening procedure. This aspect of the invention includesantagonists or agonists of NAE1-alpha identified by this methodaccording to the invention.

In a fourteenth aspect the invention provides a purified complex ofNAE1-beta and NAE1-alpha, or of NAE1-beta, NAE1-alpha and NEDD8, or apurified complex of portions thereof.

In a fifteenth aspect, the invention provides modulating ligands ofNAE1-alpha. Certain preferred modulating ligands are NAE1ABMs which actas antagonists which interfere with the ability of NAE1-alpha toparticipate in the NEDD8-activation/conjugation pathway. Other preferredmodulating ligands are NAE1ABMs which act as agonists which enhance theability of NAE1-alpha to participate in the NEDD8-activation/conjugationpathway. Preferably, such inhibition or enhancement is specific, asdescribed above. In certain embodiments, such modulating ligandspreferably interact with NAE1-alpha to inhibit or enhance the formationof NAE1 heterodimer, the formation of NEDD8 adenylate, the formation ofa thiol ester bond between NEDD8 and NAE1, and/or transfer of NEDD8 toNEDD8-conjugating enzyme.

In a sixteenth aspect, the invention provides methods for modulating theactivation and/or conjugation of NEDD8. One preferred embodiment of themethod according to this aspect of the invention comprises providing amodulating ligand NAE1-alpha or a recombinant expression unit whichexpresses NAE1-alpha or an antagonist thereof to a biological system inwhich NEDD8 is conjugated to another protein.

In a seventeenth aspect, the invention provides alleic varients of NAE-1alpha. This aspect of the invention further includes NAE1-alpha allelicvariant expression elements. Such elements include, without limitation,isolated or recombinant nucleic acid sequences encoding NAE1-alpha, ornucleic acid sequences specifically homologous or specificallycomplementary thereto, vectors comprising any such nucleic acidsequences, and recombinant expression units which express NAE1-beta orantisense transcripts or dominant negative mutants thereof.

In a eighteenth aspect, the invention provides methods for modulatingauxin response in plants. The present inventors have discovered thatNAE1-alpha shares 39% identity and 61% conserved residues with Aux1 inA. Thaliana, which is involved in signal transduction in the auxinresponse in plants. This suggests that antagonists of NAE1-beta and/orNAE1-alpha should down-regulate the auxin response, and that expressionof NAE1-beta and/or NAE1-alpha should up-regulate the auxin response.One preferred embodiment of the method according to this aspect of theinvention comprises providing a modulating ligand of NAE1-beta orNAE1-alpha or a recombinant expression unit which expresses NAE1-beta orNAE1 or an antagonist thereof to a plant that is under auxin treatment.

In a nineteenth aspect, the invention provides methods for modulatingthe biological role of APP and/or beta peptide accumulation in abiological system. The present inventors have discovered that NAE1-alphais substantially the same protein is amyloid precursor protein bindingprotein-1 (APP-BP1). This suggests that antagonists or agonists ofNAE1-beta and/or NAE1-alpha should modulate APP function, including itsrole in beta peptide accumulation. One preferred embodiment of themethod according to this aspect of the invention comprises providing amodulating ligand of NAE1-beta or NAE1-alpha or a recombinant expressionunit which expresses NAE1-beta or NAE1 or an antagonist thereof to abiological system.

In an twentieth aspect, the invention provides two new purifiedNEDD8-conjugating enzymes and allelic variants thereof. The primaryamino acid sequence of a preferred embodiment of a first suchNEDD8-conjugating enzyme (NCE1) is shown in FIG. 2. The primary aminoacid sequence of a preferred embodiment of a second suchNEDD8-conjugating enzyme (NCE2) is shown in FIG. 5.

In a twenty-first aspect, the invention provides NEDD8-conjugationenzyme expression elements. Such elements include, without limitation,isolated or recombinant nucleic acid sequences encoding NCE1 or NCE2 ordominant negative mutants thereof, or capable of expressing antisensetranscripts thereof or nucleic acid sequences specifically homologous orspecifically complementary thereto, and vectors comprising any suchrecombinant expression elements, preferably expression vectors.

The purified protein and is structural information provided hereinenables the preparation of NCE1 and NCE2 binding molecules, respectivelyNCE1BMs and NCE2BMs. Thus, in a twenty-second aspect, the inventionprovides methods for identifying NCE1BMs and NCE2BMs. One preferredmethod according to this aspect of the invention comprises screening forNCE1BMs or NCE2BMs by contacting purified NCE1 or NCE2 according to theinvention and populations of molecules or mixed populations of moleculesand determining the presence of molecules which bind specifically toNCE1 or NCE2. Another preferred method according to this aspect of theinvention comprises rationally designing molecules to bind NCE1 or NCE2based upon structural information from the purified NCE1 and NCE2provided by the invention and determining whether such rationallydesigned molecules bind specifically to NCE1 to NCE2. This aspect of theinvention includes NCE1BMs and NCE2BMs identified by the methodaccording to the invention.

NCE1BMs and NCE2BMs can be used in conventional assays to detect thepresence or absence, and/or quantity of NCE1 or NCE2, or NCE1 orNCE2/NEDD8 complex in a biological sample. Thus, in a twenty-thirdaspect, the invention provides methods for determining the presence orabsence and/or quantity of NCE1 or NCE2, or NCE1 or NCE2/NEDD8 complexin a biological sample. Such methods comprise providing a detectableNCE1BM or NCE2BM to a biological sample, allowing the detectable NCE1BMor NCE2BM to bind to, respectively NCE1 or NCE2, or respectively NCE1 orNCE2/NEDD8 complex, if any is present in biological sample, anddetecting the presence or absence and/or quantity of a complex of thedetectable NCE1BM or NCE2BM and NCE1 or NCE2, or NCE1 or NCE2/NEDD8complex.

Nucleic acid sequences specifically complementary to and/or specificallyhomologous to nucleic acid sequences encoding NCE1to NCE2 can also beused in conventional assays to detect the presence or absence of NCE1 orNCE2 nucleic acid in a biological sample. Thus, in a twenty-fourthaspect, the invention provides methods for determining the presence orabsence and/or quantity of NCE1 or NCE2 nucleic acid in a biologicalsample. In preferred embodiments, such assays are nucleic acidhybridization and/or amplification assays, such assays comprisingproviding to the biological sample a nucleic acid sequence which isspecifically complementary to NCE1 or NCE2 nucleic acid.

In a twenty-fifth aspect, the invention provides methods for identifyingmodulating ligands of NCE1 or NCE2. Some NCE1BMs or NCE2BMs are capableof acting as antagonists or agonists of, respectively NCE1 or NCE2.Thus, the method according to this aspect of the invention comprisesproviding NCE1BMs or NCE2BMs to an assay system for NCE1 or NCE2participation in the NEDD8-activation/conjugation pathway, anddetermining whether such NCE1BMs or NCE2BMs interfere with or enhancethe ability of NCE1 or NCE2 to participate in theNEDD8-activation/conjugation pathway. The NCE1BMs or NCE2BMs arepreferably provided as a population of molecules (most preferablyrationally designed molecules), or as a mixed population of molecules,as for example in a screening procedure. This aspect of the inventionincludes modulating ligands of NCE1 or NCE2 identified by this inventionaccording to the invention.

In a twenty-sixth aspect, the invention provides modulating ligands ofNCE1or NCE2. Preferred modulating ligands are NCE1BMs or NCE2BMs whichact as antagonists, interfering with the ability of NCE1 or NCE2 toparticipate in the NEDD8-activation/conjugation pathway. Other preferredmodulating ligands are NCE1BMs or NCE2BMs which act as agonists,enhancing the ability of, respectively NCE1 or NCE2 to participate inthe NEDD8-activation/conjugation pathway. In certain embodiments, suchNCE1BMs or NCE2BMs preferably interact with NCE1 or NCE2 to inhibit orenhance the formation of a thiol ester bond between NEDD8 and NCE1 toNCE2 and/or transfer of NEDD8 to its target protein.

In a twenty-seventh aspect, the invention provides methods formodulating the conjugation of NEDD8 or its transfer to a target protein.One preferred embodiment of the method according to this aspect of theinvention comprises providing a modulating ligand of NCE1 or NCE2 or arecombinant expression unit which expresses NCE1 or NCE2 or anantagonist thereof to a biological system in which NEDD8 is conjugatedto another protein.

In a twenty-eighth aspect, the invention provides oligonucleotides thatare specifically complementary to a portion of a nucleotide sequenceshown in FIG. 2 or FIG. 5. Preferred embodiments include hybridizationprobes and antisense oligonucleotides.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the nucleotide [SEQ. ID. NO. 1] and predicted amino acidsequence [SEQ. ID. NO. 2] for NAE1-beta, with the two tryptic peptidesequences highlighted by underline.

FIG. 2 shows the nucleotide [SEQ. ID. NO. 3] and predicted amino acidsequence [SEQ. ID. NO. 4] for NEDD8 -conjugating enzyme 1 (NCE1), withthe active Cys residue indicated.

FIG. 3 shows the alignment of NCE1 with yeast Ubc12.

FIG. 4 shows results of an assay for thioester bond formation betweenNEDD-8 and NCE1.

FIG. 5 shows the nucleotide [SEQ. ID. NO.5] and predicted amino acidsequence [SEQ. ID. NO. 6] for NEDD-8-conjugating enzyme 2 (NCE2) withthe active Cys residue indicated.

FIG. 6 shows homology between NCE2 and a C. elegans gene of unknownfunction.

FIG. 7 shows the sequence alignment of NCE1 and NCE2 with known Ubcproteins.

FIG. 8 shows results of an assay for thioester bond formation betweenNEDD8 and NCE2.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The invention relates to covalent modification of proteins through theirconjugation with other proteins. More particularly, the inventionrelates to the modulation of such conjugation involving the proteinNEDD8. The invention provides compositions and methods for detectingand/or modulating the conjugation of NEDD8 and/or its transfer to atarget protein, as well as compositions and methods for discoveringmolecules which are useful in detecting and/or modulating theconjugation of NEDD8 and/or its transfer to a target protein. Thepresent invention arises from the purification and characterization ofnovel NEDD8 activating and conjugating enzymes.

The patents and publications cited herein reflect the knowledge in theart and are hereby incorporated by reference in entirety. Anyinconsistency between these patents and publications and the presentdisclosure shall be resolved in favor of the present disclosure.

In a first aspect, the invention provides purified NEDD8-activatingprotein beta subunit (NAE1-beta). The primary amino acid sequence of apreferred embodiment of such NAE1-beta protein is shown in FIG. 1.However, the term “NEDD8-activating protein beta subunit”, or“NAE1-beta”, is intended to include allelic variants thereof. An“allelic variant”, as used herein, is a protein having at least about75% amino acid sequence, preferably at least about 85% more preferablyat least about 95%, and most preferably at least about 99% identity tothe amino acid sequence set forth in SEQ ID NO 2, or to a portion orprotein conjugate thereof which retains the biological activity ofNAE1-beta (as part of the NAE1 heterodimer) to form a thioester linkagewith NEDD8 at a rate faster than the achieved by human ubiquitinactivating enzyme 1, preferably at least 2-fold faster, more preferablyat least 5-fold and most preferably at least 10-fold. Alternatively, analleic variant can retain such biological activity and comprise apeptide sequence having at least 70% amino acid identity to the peptidesequence corresponding to residues 46-118 in FIG. 1, or at least 45%amino acid identity to the peptide sequence corresponding to residues119-166, at least 55% amino acid identity to the peptide sequencecorresponding to residues 175-239, or at least 35% amino acid identityto the peptide sequence corresponding to residues 276-375. Preferablysuch biologically active portion comprises at least the PXCT motif,wherein X can be any amino acid, preferably a hydrophobic amino acid,more preferably methionine, leucine, or isoleucine, and most preferablymethionine. More preferably, such biologically active portion comprisesamino acid sequence of residues 214-217, more preferably comprises atleast about 25 additional amino acids of NAE1-beta, even more preferablyat least about 50 additional amino acids of NAE1-beta, still morepreferably at least about 75 additional amino acids of NAE1-beta, yeteven more preferably at least about 100 additional amino acids ofNAE1-beta, most preferably at least about 150 additional amino acidsfrom NAE1-beta. Such allelic variants have the biological activity ofNAE1-beta, as discussed above, which is the catalytic monomer of theNAE1 heterodimer. In alternative preferred embodiments, such allelicvariants are either rationally designed or naturally occurring allelicvariants, i.e., they are expressed in actual individual mammals, mostpreferably from actual individual humans or mice. Rationally designedallelic variants can be produced according to standard art-recognizedprocedures (e.g., international publication WO95/18974). “Purified”, asused herein means having less than about 25% by weight, and preferablyless than about 10% by weight contamination with other proteins. Suchpurified proteins may be obtained from natural sources, from recombinantexpression, or by chemical synthesis. “Protein”, as used herein andhereinbelow is intended to encompass any polypeptide having at least 10amino acid residues.

In a second aspect, the invention provides NAE1-beta expressionelements. Such elements include, without limitation, isolated orrecombinant nucleic acid sequences encoding NAE1-beta or dominantnegative mutants thereof, or capable of expressing antisense transcriptsthereof or nucleic acid sequences specifically homologous orspecifically complementary thereto, and vectors comprising any suchrecombinant expression elements, preferably expression vectors.

For purposes of the invention, amino acid sequence identity and homologyare determined using the program Clustal W Version 1.6 to do sequencealignment (Thompson et al., Nucleic Acids Res 22: 4673-4680 (1994)). Forviewing aligned sequences, the program GeneDoc Version 2.2 was used. Asequence is “specifically homologous” to another sequence if it issufficiently homologous to specifically hybridize to the exactcomplement of the sequence. A sequence is “specifically complementary”to another sequence if it is sufficient homologous to specificallyhybridize to the sequence. A sequence “specifically hybridizes” toanother sequence if it hybridizes to form Watson-Crick or Hoogsteen basepairs either in the body, or under conditions which approximatephysiological conditions with respect to ionic strength, e.g., 140 mMNaCl, 5 mM MgCl₂. Preferably, such specific hybridization is maintainedunder stringent conditions, e.g., 0.2× SSC at 68° C. A “recombinantexpression element” is a nucleic acid sequence which encodes NAE1-beta,or a portion encoding at least 15 contiguous amino acids thereof, or adominant negative mutant thereof, or is capable of expressing anantisense molecule specifically complementary thereto, or a sensemolecule specifically homologous thereto wherein the recombinantexpression unit may be in the form of linear DNA or RNA, covalentlyclosed circular DNA or RNA, or as part of a chromosome, provided howeverthat it cannot be the native chromosomal locus for NAE1-beta. Preferredrecombinant expression elements are vectors, which may include an originof replication and are thus replicable in or more cell type. Certainpreferred recombinant expression elements are expression vectors, andfurther comprise at least a promoter and passive terminator, therebyallowing transcription of the recombinant expression element in abacterial, fungal, plant, insect or mammalian cell. Preferredrecombinant expression elements have at least 75% nucleic acid sequenceidentity with the nucleic acid sequence set forth in SEQ ID NO 1, morepreferably at least 90%, even more preferably at least 95%, and mostpreferably at least 99%, and encode a protein or peptide having eitherNAE1-beta biological activity, as described above, or activity as adominant negative mutant thereof, as further described below.

“Dominant negative mutants” are proteins derived from NAE1-beta orNAE1-alpha which inhibit the biological activity of NAE1. Preferreddominant negative mutants include allelic variants in which the C atposition 216 is substituted, preferably by S. Additional preferreddominant negative mutants interfere with association of native NAE1-betawith native NAE1-alpha and can be derived from either NAE1-beta andNAE1-alpha. Such dominant negative mutants can be prepared by artrecognized procedures (see e.g., Townsley et al., Proc. Natl. Acad. Sci.USA 94: 2362-2367 (1997)). Preferably, such dominant negative mutant isa protein or peptide having from 50% amino acid sequence identity toabout 99% identity to the amino acid sequence set forth in SEQ ID NO 2,or to a portion or protein conjugate thereof which inhibits thebiological activity of NAE1 to form a thioester linkage with NEDD8 ortransfer NEDD8 to a NEDD8 conjugating enzyme, under conditions asdescribed in the following examples by at least 50%, preferably by atleast 75%, more preferably by at least 90% and most preferably by atleast 99%. Preferably, such inhibitory portion comprises an amino acidsequence spanning residue 216, more preferably comprises at least about25 additional amino acids of NAE1-beta, or at least about 50 additionalamino acids of NAE1-beta, or at least about 75 additional amino acids ofNAE1-beta, or at least about 100 additional amino acids of NAE1-beta, oreven at least about 150 additional amino acids of NAE1-beta. Forpurposes of this aspect of the invention, the term “spanning residue216” means comprising amino acid residues in both the N-terminal andC-terminal directions from residue 216, as that residue is shown in FIG.1. Preferably, residue 216 itself may be substituted by one or moreamino acids, more preferably from about 1 to about 50 amino acids, orresidue 216 may be absent. Preferably the amino acids in the N-terminaland C-terminal directions from residue 216 are each independently within20 amino acids of residue 216, as shown in FIG. 1, more preferablywithin 10, even more preferably within 5, and most preferably areimmediately adjacent residue 216 as shown in FIG. 1.

The purified protein and its structural information provided hereinenables the preparation of NAE1-beta-binding molecules (NAE1BBMs). Thus,in a third aspect, the invention provides methods for identifyingNAE1BBMs. One preferred method according to this aspect of the inventioncomprises screening for NAE1BBMs by contacting purified NAE1-betaaccording to the invention and populations of molecules or mixedpopulations of molecules and determining the presence of molecules whichbind specifically to NAE1-beta. Another preferred method according tothis aspect of the invention comprises rationally designing molecules tobind NAE1-beta based upon structural information from the purifiedNAE1-beta protein and amino acid sequence disclosed herein provided bythe invention and determining whether such rationally designed moleculesbind specifically to NAE1-beta. Molecules that bind specifically toNAE1-beta are molecules that bind to NAE1-beta with greater affinitythan to other unrelated proteins. Preferably, binding affinity of themolecule is at least 5-fold greater than affinity for unrelatedproteins, more preferably at least 10-fold greater, still morepreferably at least 50-fold greater, and most preferably at least100-fold greater. This aspect of the invention includes NAE1BBMsidentified by the methods according to the invention.

As used herein, a “NAE1-beta-binding molecule”, or “NAE1BBM”, is amolecule or macromolecule which binds under physiological conditions toNAE1-beta. “Binds under physiological conditions” means forming acovalent or non-covalent association with an affinity of at least 10⁶M⁻¹, most preferably at least 10⁹ M⁻¹, either in the body, or underconditions which approximate physiological conditions with respect toionic strength, e.g., 140 mM NaCl, 5 mM MgCl₂. A “population ofmolecules”, as used herein, refers to a plurality of identicalmolecules. A “mixed population of molecules” refers to a plurality ofmolecules wherein more than one type of molecule is present.

In certain preferred embodiments, an NAE1BBM according to the inventionis a peptide or a peptidomimetic. For purposes of the invention, a“peptide” is a molecule comprised of a linear array of amino acidresidues connected to each other in the linear array by peptide bonds.Such peptides according to the invention may include from about three toabout 500 amino acids, and may further include secondary, tertiary orquaternary structures, as well as intermolecular associations with otherpeptides or other non-peptide molecules. Such intermolecularassociations may be through, without limitation, covalent bonding (e.g.,through disulfide linkages), or through chelation, electrostaticinteractions, hydrophobic interactions, hydrogen bonding, ion-dipoleinteractions, dipole—dipole interactions, or any combination of theabove.

In certain preferred embodiments, such an NAE1BBM comprises acomplementarity determining region of an antibody which binds underphysiological conditions to a peptide-containing epitope of NAE1-beta,or a peptidomimetic of such a complementarity determining region. Forpurposes of the invention, a “complementary determining region of anantibody” is that portion of an antibody which binds under physiologicalconditions to an epitope, including any framework regions necessary forsuch binding, and which is preferably comprised of a subset of aminoacid residues encoded by the human heavy chain V, D and J regions, thehuman light chain V and J regions, and/or combinations thereof. Examplesof such preferred embodiments include an antibody, or an antibodyderivative, which may more preferably be a monoclonal antibody, a humanantibody, a humanized antibody, a single-chain antibody, a chimericantibody, or an antigen-binding antibody fragment.

Those skilled in the art are enabled to make any such antibodyderivatives using standard art-recognized techniques. For example, Joneset al., Nature 321: 522-525 (1986) discloses replacing the CDRs of ahuman antibody with those from a mouse antibody. Marx, Science 229:455-456 (1985) discusses chimeric antibodies having mouse variableregions and human constant regions. Rodwell, Nature 342: 99-100 (1989)discusses lower molecular weight recognition elements derived fromantibody CDR information. Clackson, Br. J. Rheumatol. 3052: 36-39 (1991)discusses genetically engineered monoclonal antibodies, including Fvfragment derivatives single chain antibodies, fusion proteins chimericantibodies and humanized rodent antibodies. Reichman et al., Nature 332:323-327 (1988) discloses a human antibody on which rat hypervariableregions have been grafted. Verhoeyen, et al., Science 239: 1534-1536(1988) teaches grafting of a mouse antigen binding site onto a humanantibody.

In addition, those skilled in the art are enabled to design and producepeptidomimetics having binding characteristics similar or superior tosuch complementarity determining region (see e.g., Horwell et al.,Bioorg. Med. Chem. 4: 1573 (1996); Liskamp et al., Recl. Trav. Chim.Pays- Bas1: 113 (1994); Gante et al., Angew. Chem. Int. Ed. Engl. 33:1699 (1994); Seebach et al., Helv. Chim. Acta 79: 913 (1996)).Accordingly, all such antibody derivatives and peptidomimetics thereofare contemplated to be within the scope of the present invention.Compositions according to the invention may further includephysiologically acceptable diluents, stabilizing agents, localizingagents or buffers.

Additional preferred NAE1BBMs according to the invention include smallmolecules, which can be identified using screening or rational designapproaches as discussed later herein.

NAE1BBMs can be used in conventional assays to detect the presence orabsence, and or quantity of NAE1-beta, NAE1 heterodimer, or NAE1heterodimer/NEDD8 complex in a biological sample. Thus, in a fourthaspect, the invention provides methods for determining the presence orabsence and/or quantity of NAE1-beta, NAE1 heterodimer, or NAE1heterodimer/NEDD8 complex in a biological sample. Such methods compriseproviding a detectable NAE1BBM to a biological sample, allowing thedetectable NAE1BBM to bind to NAE1-beta, NAE1 heterodimer, or NAE1heterodimer/NEDD8 complex, if any is presen in the biological sample,and detecting the presence or absence/or quantity of a complex of thedetectable NAE1BBM and NAE1-beta, NAE1-heterodimer, or NAE1heterodimer/NEDD8 complex.

A detectable NAE1BBM is an NAE1BBM which can be detected in an assay.Such detection is preferably through the direct or indirect binding of atag or label on the NAE1BBM. “Direct or indirect binding” means that thetag or label may be directly connected to the NAE1BBM by intermolecularassociation, or may be connected via intermediate molecules to theNAE1BBM by intermolecular association. Such intermolecular associationsmay be through, without limitation, covalent bonding (e.g., throughdisulfide linkages), or through chelation, electrostatic interactions,hydrophobic interactions, hydrogen bonding, ion-dipole interactions,dipole—dipole interactions, or any combination of the above. Preferredtags and labels include, without limitation, radioisotopes, heavymetals, fluorescent labels, chemoluminescent labels, enzymes and enzymesubstrates. Preferred biological samples include blood, serum, plasma,cells, tissue portions, and cell or tissue extracts. In certainpreferred embodiments, the method according to this aspect of theinvention takes the form of a conventional ELISA or RIA. In anotherpreferred embodiment, the method employs either direct or indirectimmunofluorescence. Additional preferred embodiments utilize in vivoimaging of cells expressing NAE1-beta using conventional imaging agentsdirectly or indirectly bound to an NAE1BBM according to the invention.

Nucleic acid sequences specifically complementary to and/or specificallyhomologous to nucleic acid sequences encoding NAE1-beta can also be usedin conventional assays to detect the presence or absence of NAE1-betanucleic acid in a biological sample. Thus, in a fifth aspect, theinvention provides methods for determining the presence or absenceand/or quantity of NAE1-beta nucleic acid in a biological sample. Inpreferred embodiments, such assays are nucleic acid hybridization and/oramplification assays, such assays comprising providing to the biologicalsample a nucleic acid sequence which is specifically complementary toNAE1-beta nucleic acid. Particularly, preferred embodiments includeNorthern blotting, dot or slot blotting, and polymerase chain reaction.

In a sixth aspect, the invention provides methods for identifyingmodulating ligands of NAE1-beta. Some NAE1BBMs are capable of acting asantagonists or agonists of NAE1-beta. Thus, the method according to thisaspect of the invention comprises providing NAE1BBMs to an assay systemfor NAE1-beta participation in the NEDD8-activation/conjugation pathway,and determining whether such NAE1BBMS interfere with or enhance theability of NAE1-beta to participate in the NEED8-activation/conjugationpathway. The NAE1BBMs are preferably provided as a population ofmolecules (most preferably rationally designed molecules), or as a mixedpopulation of molecules, as for example in a screening procedure. Thisaspect of the invention includes antagonists or agonists of NAE1-betaidentified by this method according to the invention. Assessment ofability to “interfere with or enhance the ability to participate in theNEDD8-activation/conjugation pathway” can conveniently be carried outusing an in vitro activity system, as later described herein.Preferably, such interference or enhancement results in a reduction ofNEDD8 activation/conjugation of at least 50%, more preferably at least90%, and most preferably, at least 99%, or an increase of NEDD8activation/conjugation of at least 50%, preferably at least 2-fold, thepreferably at least 5-fold.

In a seventh aspect, the invention provides modulating ligands ofNAE1-beta. Preferred modulating ligands are NAE1BBMs which act asantagonists, interfering with the ability of NAE1-beta to participate inthe NEDD8-activation/conjugation pathway. Other preferred modulatingligands are NAE1BBMs which act as agonists, enhancing the ability ofNAE1-beta to participate in the NEDD8-activation/conjugation pathway.Preferably, such inhibition or enhancement is specific, i.e., themodulating ligand interferes with or enhances the ability of NAE1-betato participate in the NEDDS activation/conjugation pathway at aconcentration that is lower than the concentration of the ligandrequired to produce another, unrelated biological effect. Preferably,the concentration of the ligand required for NEDD8activation/conjugation modulating activity is at least 2-fold lower,more preferably at least 5-fold lower, even more preferably at least10-fold lower, and most preferably at least 20-fold lower than theconcentration required to produce an unrelated biological effect. Incertain embodiments, such NAE1BBMs preferably interact with NAE1-beta toinhibit or enhance the formation of NAE1 heterodimer, the formation ofNEDD8 adenylate, the formation of a thiol ester bond between NEDD8 andNAE1, and/or transfer of NEDD8 to NEDD8-conjugating enzyme.

In an eighth aspect, the invention provides methods for modulating theconjugation of NEDD8 to NAE1 or its transfer to a NEDD8 conjugatingenzyme or a target protein. One preferred embodiment of the methodaccording to this aspect of the invention comprises providing amodulating ligand of NAE1-beta or a recombinant expression unit whichexpresses NAE1-beta or an antagonist thereof to a biological system inwhich NEDD8 is conjugated to a NEDDS conjugating enzyme or a targetprotein.

The term “biological system”, as used herein, includes in vitro cell ortissue extracts, cell cultures, tissue cultures, organ cultures, livingplants and animals, including mammals, including without limitationhumans and mice. An “antagonist” is a molecule which inhibits thebiological activity of NAE1.

In a ninth aspect, the invention provides oligonucleotides that arespecifically complementary to a portion of a nucleotide sequence shownin FIG. 1. Preferred embodiments include hybridization probes andantisense oligonucleotides.

For purposes of the invention, the term oligonucleotide includespolymers of two or more deoxyribonucleotide, or any modified nucleoside,including 2′-halo-nucleosides, 2′-O-substituted ribonucleosides,deazanucleosides or any combination thereof. Preferably, sucholigonucleotides have from about 10 to about 100 nucleosides, morepreferably from about 15-50, and most preferably from about 15 to 35.Such monomers may be coupled to each other by any of the numerous knowninternucleoside linkages. In certain preferred embodiments, theseinternucleoside linkages may be phosphodiester, phosphotriester,phosphorothioate, or phosphoramidate linkages, or combinations thereof.The term oligonucleotide also encompasses such polymers havingchemically modified bases or sugars and/or having additionalsubstituents, including without limitation lipophilic groups,intercalating agents, diamines and adamantane. For purposes of theinvention the term “2′-O-substituted” means substitution of the 2′position of the pentose moiety with a halogen (preferably Cl, Br, or F),or an O-lower alkyl group containing 1-6 saturated or unsaturated carbonatoms, or with an O-aryl or allyl group having 2-6 carbon atoms, whereinsuch alkyl, aryl or allyl group may be unsubstituted or may besubstituted, e.g., with halo, hydroxy, trifluoromethyl, cyano, nitro,acyl, acyloxy, alkoxy, carboxyl, carbalkoxyl, or amino groups, or such2′ substitution may be with a hydroxy group (to produce aribonucleoside), an amino or a halo group, but not with a 2′-H group.Certain embodiments of such oligonucleotides are useful in hybridizationassays. Other embodiments are useful as antisense oligonucleotides foruse in animal model or human therapeutic settings.

In a tenth aspect, the invention provides methods for identifyingNAE1-alpha binding molecules (NAE1ABMs). The present inventors haveidentified the alpha subunit of the NAE1 heterodimer (NAE1-alpha).Surprisingly, it has an amino acid sequence which is substantiallyidentical to a protein previously identified as amyloid precursorprotein binding protein 1 (APP-BP1; see Chow et al. J. Biol. Chem. 271:11339-11346 (1996)) One preferred method according to this aspect of theinvention comprises screening for NAE1ABMs by contacting purifiedNAE1-alpha and populations of molecules or mixed populations ofmolecules and determining the presence of molecules which bindspecifically to NAE1-alpha, or preferably to NAE1 heterodimer. Anotherpreferred method according to this aspect of the invention comprisesrationally designing molecules to bind NAE1-alpha based upon structuralinformation from the NEA1-alpha protein identified by the presentinventors and determining whether such rationally designed moleculesbind specifically to NAE1-alpha. This aspect of the invention includesNAE1ABMs identified by the methods according to the invention.

The terms “bind specifically”, “population of molecules” and “mixedpopulation of molecules” are as described previously. Structural aspectsof NAE1ABMs are as discussed above for NAE1BBMs, except that NAE1ABMsbind under physiological conditions to NAE1-alpha. Preferably, bindingaffinity of the molecule for NAE1-alpha is at least 5-fold greater thanaffinity for unrelated proteins, more preferably at least 10-foldgreater, still more preferably at least 50-fold greater, and mostpreferably at least 100-fold greater. This aspect of the inventionincludes NAE1ABMs identified by the methods according to the invention.

As used herein, a “NAE1-alpha-binding molecule”, or “NAE1ABM”, is amolecule or macromolecule which binds under physiological conditions toNAE1-alpha. The terms “binds under physiological conditions”,“population of molecules”, and “mixed population of molecules” are asused previously.

In certain preferred embodiments, an NAE1ABM according to the inventionis a peptide or a peptidomimetic. For purposes of the invention, theterm “peptide” is as used previously.

In certain preferred embodiments, such an NAE1ABM comprises acomplementarity determining region of an antibody which binds underphysiological conditions to a peptide-containing epitope of NAE1-alpha,or a peptidomimetic of such a complementarity determining region. Forpurposes of the invention, the term “complementarity determining regionof an antibody” is as used previously. Compositions according to theinvention may further include physiologically acceptable diluents,stabilizing agents, localizing agents or buffers.

Additional preferred NAE1ABMs according to the invention include smallmolecules, which can be identified using screening or rational designapproaches as discussed later herein.

NAE1ABMs can be used in conventionally assays to detect the pressure orabsence, and/or quantity of NAE1-alpha, NAE1 heterodimer, or NAE1heterodimer/NEDD8 complex in a biological sample. Thus, in an eleventhaspect, the invention provides methods for determining the presence orabsence and/or quantity of NAE1-alpha, NAE1 heterodimer, or NAE1heterodimer/NEDD8 complex in a biological sample. Such methods compriseproviding a detectable NAE1ABM to a biological sample, allowing thedetectable NAE1ABM to bind to NAE1-alpha, NAE1 heterodimer, or NAE1heterodimer/NEDD8 complex, if any is present in the biological sample,and detecting the presence or absence and/or quantity of a complex ofthe detectable NAE1ABM and NAE1-alpha, NAE1-heterodimer, or NAE1heterodimer/NEDD8 complex.

A detectable NAE1ABM is an NAE1ABM which can be detected in an assay.Such detection is preferably through the direct or indirect binding of atag or label on the NAE1ABM. The term “direct or indirect binding” is asused previously. Preferred tags and labels include, without limitation,radiosotopes, heavy metals, fluorescent labels, chemoluminescent labels,enzymes and enzyme substrates. Preferred biological samples includeblood, serum, plasma, cells, tissue portions, and cell or tissueextracts. In certain preferred embodiments, the method according to thisaspect of the invention takes the form of a conventional ELISA or RIA.In another preferred embodiment, the method employs either direct orindirect immunofluorescence. Additional preferred embodiments utilize invivo imaging of cells expressing NAE1-alpha using conventional imagingagents directly or indirectly bound to an NAE1ABM according to theinvention.

Nucleic acid sequences specifically complementary to and/or specificallyhomologous to nucleic acid sequences encoding NAE1-alpha can also beused in conventional assays to detect the presence or absence ofNAE1-alpha nucleic acid in a biological sample. Thus, in a twelfthaspect, the invention provides methods for determining the presence orabsence and/or quantity of NAE1-alpha nucleic acid in a biologicalsample. In preferred embodiments, such assays are nucleic acidhybridization and/or amplification assays, such assays comprisingproviding to the biological sample a nucleic acid sequence which isspecifically complementary to NAE1-alpha nucleic acid. Particularlypreferred embodiments include Northern blotting, dot or slot blotting,and polymerase chain reaction.

In a thirteenth aspect, the invention provides methods for identifyingmodulating ligands of NAE1-alpha. Some NAE1ABMs are capable of acting asantagonists or agonists of NAE1-alpha. Thus, the method according tothis aspect of the invention comprises providing NAE1ABMs to an assaysystem for NAE1-alpha participation in the NEDD8-activation/conjugationpathway, and determining whether such NAE1ABMs interfere with or enhancethe ability of NAE1-alpha to participate in theNEDD8-activation/conjugation pathway. The NAE1ABMs are preferablyprovided as a population of molecules (most preferably rationallydesigned molecules), or as a mixed population of molecules, as forexample in a screening procedure. This aspect of the invention includesantagonists or agonists of NAE1-alpha identified by this methodaccording to the invention. Assessment of ability to “interfere with orenhance the ability to participate in the NEDD8-activation/conjugationpathway” can conventionally be carried out using an in vitro activitysystem, as later described herein. Preferably, such interference orenhancement results in a reduction of NEDD8 activation/conjugation of atleast 50%, more preferably at least 90%, and most preferably, at least99%, or an increase of NEDD8 activation/conjugation of at least 50%,preferably at least 2-fold, more preferably at least 5-fold.

In a fourteenth aspect the invention provides a purified complex ofNAE1-beta and NAE1-alpha, or NAE1-beta, NAE1-alpha and NEDD8, or apurified complex of portions thereof. The term “complex” means incovalent or noncovalent association, preferably with an affinity greaterthan 10⁶/mole. The term “purified” is as used previously.

In a fifteenth aspect, the invention provides modulating ligands ofNAE1-alpha. Preferred modulating ligands as NAE1ABMs which act asantagonists, interfering with the ability of NAE1-alpha to participatein the NEDD8-activation/conjugation pathway. Other preferred modulatingligands are NAE1ABMs which act as agonists, enhancing the ability ofNAE1-alpha to participate in the NEDD8-activation/conjugation pathway.Preferably, such inhibition or enhancement is specific, i.e., themodulating ligand interferes with or enhances the ability of NAE1-alphato participate in the NEDD8 activation/conjugation pathway at aconcentration that is lower than the concentration of the ligandrequired to produce another, unrelated biological effect. Preferably,the concentration of the ligand required for NEDD8activation/conjugation modulating activity is at least 2-fold lower,more preferably at least 5-fold lower, even more preferably at least10-fold lower, and most preferably at least 20-fold lower than theconcentration required to produce an unrelated biological effect. Incertain embodiments, such NAE1ABMs preferably interact with NAE1-alphato inhibit or enhance the formation of NAE1 heterodimer, the formationof NEDD8 adenylate, the formation of a thiol ester bond between NEDD8and NAE1, and/or transfer of NEDD8 to NEDD8-conjugating enzyme.

In a sixteenth aspect, the invention provides methods for modulating theconjugation of NEDD8 to NAE1 or its transfer to a NEDD8 conjugatingenzyme or a target protein. One preferred embodiment of the methodaccording to this aspect of the invention comprises providing amodulating ligand of NAE1-alpha or a recombinant expression unit whichexpresses NAE1-alpha or an antogonist thereof to a biological system inwhich NEDD8 is conjugated to a NEDD8 conjugating enzyme or a targetprotein.

The term “biological system”, as used herein, includes in vitro cell ortissue extracts, cell cultures, tissue cultures, organ cultures, livingplants and animals, including mammals, including without limitationhumans and mice. An “antagonist” is a molecule which inhibits thebiological activity of NAE1.

In a seventeenth aspect, the invention provides allelic variants ofNAE-1 alpha. An “allelic variant”, as used herein, is a protein havingat least about 75% amino acid sequence, preferably at least about 85%,more preferably at least about 95%, and most preferably at least about99% identity to the amino acid sequence of NAE1-alpha, or to a portionor protein conjugate thereof which retains the biological activity ofNAE1-alpha to form a heterodimer with NAE1-beta which is active in theNEDD8 activation/conjugation pathway. This aspect of the inventionfurther includes NAE1-alpha allelic variant expression elements. Suchelements include, without limitation, isolated or recombinant nucleicacid sequences encoding NAE1-alpha, or nucleic acid sequencesspecifically homologous or specifically complementary thereto, vectorscomprising any such nucleic acid sequences, and recombinant expressionunits which express NAE1-beta or antisense transcripts or dominantnegative mutants thereof. Each of these terms is as used previously.

In a eighteenth aspect, the invention provides methods for modulatingauxin response in plants. The present inventors have discovered thatNAE1-alpha shares 39% identity and 61% conserved residues with Aux1 inA. Thaliana, which is involved in signal transduction in the auxinrespone in plants. This suggests that antagonists of NAE1-beta and/orNAE1-alpha should down-regulate the auxin response, and that expressionof NAE1beta and/or NAE1-alpha should up-regulate the auxin response (seeLeyser et al., Nature 364: 161-164 (1993)). One preferred embodiment ofthe method according to this aspect of the invention comprises providinga modulating ligand of NAE1-beta or NAE1-alpha or a recombinantexpression unit which expresses NAE1-beta or NAE1 or an antagonistthereof to a plant that is undergoing auxin treatment.

In a nineteenth aspect, the invention provides methods for modulatingthe biological function of APP and/or beta peptide accumulation in abiological system. The present inventors have discovered that NAE1-alphais substantially the same protein as amyloid precursor protein bindingprotein-1 (APP-BP1). This suggests that antagonists or agonists ofNAE1-beta and/or NAE1-alpha should modulate APP function, including itsrole in beta peptide accumulation. One preferred embodiment of themethod according to this aspect of the invention comprises providing amodulating ligand of NAE1-beta or NAE1-alpha or a recombinant expressionunit which expresses NAE1-beta or NAE1 or an antagonist thereof to abiological system.

In a twentieth aspect, the invention provides two new purifiedNEDD8-conjugating enzymes. The primary amino acid sequence of apreferred embodiment of a first such NEDD8-conjugating enzyme (NCE1) isshown in FIG. 2. The primary amino acid sequence of a preferredembodiment of a second such NEDD8-conjugating enzyme (NCE2) is shown inFIG. 5. However, the terms “NEDD8-conjugating enzyme 1”, “NCE1”,“NEDD8-conjugating enzyme 2”, and “NCE2” are intended to include allelicvariants thereof. An “allelic variant”, are used herein, is a proteinhaving at least about 50% amino acid sequence identity, more preferablyat least about 75%, even more preferably at least about 85%, still morepreferably at least about 95%, and most preferably at least about 99%identity to the amino acid sequence set forth in SEQ ID NO 4 or SEQ IDNO 6, or to a portion or protein conjugate thereof which retains thebiological activity of NCE1 or NCE2 to form a thioester linkage withNEDD8 under conditions as described in the examples below at a rateleast 10% of that of NCE1 or NCE2, preferably at least 25% as fast, morepreferably at least 50% as fast, and most preferably at least 75% asfast. Preferably, such biologically active portion comprises an aminoacid sequence spanning residue 111 in FIG. 2 or residue 116 in FIG. 5,more preferably comprises at least about 25 additional amino acids ofrespectively NCE1 or NCE2, even more preferably at least about 50additional amino acids of respectively NCE1 or NCE2, still morepreferably at least about 75 additional amino acids of respectively NCE1or NCE2, yet even more preferably at least about 100 additional aminoacids of respectively NCE1 or NCE2, most preferably at least about 150additional amino acids from respectively NCE1 or NCE2. Such allelicvariants have the biological activity of NCE1 or NCE2, as discussedabove. In alternative preferred embodiments, such allelic variants areeither rationally designed or naturally occurring allelic variants,i.e., they are expressed in actual individual mammals, most preferablyfrom actual individual humans or mice. Rationally designed allelicvariants can be produced according to standard art-recognized procedures(see e.g., international publication WO95/18974). The terms “purified”and “protein” are as used previously.

In a twenty-first aspect, the invention provides NEDD8-conjugationenzyme expression elements. Such elements include, without limitation,isolated or recombinant nucleic acid sequences encoding NCE1 or NCE2 ordominant negative mutants thereof, or capable of expressing antisensetranscripts thereof or nucleic acid sequences specifically homologous orspecifically complementary thereto, and vectors comprising any suchrecombinant expression elements, preferably expression vectors.

The terms “specifically homologous”, “specifically complementary” and“specifically hybridizes” are as used previously. A “recombinantexpression element” is a nucleic acid sequence which encodes NCE1 orNCE2, or a portion encoding at least 20 contiguous amino acids thereof,or a dominant negative mutant thereof, or is capable of expressing anantisense molecule specifically complementary thereto, or a sensemolecule specifically homologous thereto wherein the recombinantexpression unit may be in the form of linear DNA or RNA, covalentlyclosed circular DNA or RNA, or as part of a chromosome, provided howeverthat it cannot be the native chromosomal locus for NCE1 or NCE2.Preferred recombinant expression elements are vectors, which may includean origin of replication and are thus replicatable in one or more celltype. Certain preferred recombinant expression elements are expressionvectors, and further comprise at least a promoter and passiveterminator, thereby allowing transcription of the recombinant expressionelement in a bacterial, fungal, plant, insect or mammalian cell.Preferred recombinant expression elements have at least 75% nucleic acidsequence identity with the nucleic acid sequence set forth in SEQ ID NO2 OR SEQ ID NO 4, more preferably at least 90%, even more preferably atleast 95%, and most preferably at least 99%, and encode a protein orpeptide having either NCE1 or NCE2 biological activity or activity as adominant negative mutant thereof, as further described below.

“Dominant negative mutants” are proteins or peptides derived from NCE1or NCE2 which inhibit the biological activity of, respectively NCE1 orNCE2. Preferred dominant negative mutants include variants in which theC at position 111 of NCE1 or position 116 of NCE2 is substituted,preferably by S. Preferred dominant negative mutants interfere withassociation of NEDD8 and NCE1 or NCE2 and can be derived fromrespectively, NCE1 or NCE2. Other preferred dominant negative mutantsinterfere with conjugation of NEDD8 to a target protein and can bederived from either NCE1 or NCE2. Such dominant negative mutants can beprepared by art recognized procedures (see e.g., Townsley et al., Proc.Natl. Acad. Sci. USA 94: 2362-2367 (1997)). Preferably, such dominantnegative mutant is a protein or peptide having from 50% amino acidsequence identity to about 99% identity to the amino acid sequence setforth in SEQ ID NO 3 or SEQ ID NO 5, or to a portion or proteinconjugate thereof which inhibits the biological activity of NCE1 or NCE2to form a thioester linkage with NEDD8 under conditions as described inthe following examples by at least 50%, preferably by at least 75%, morepreferably by at least 90% and most preferably by at least 99%.Preferably, such inhibitory portion comprises an amino acid sequencespanning residue 111 in FIG. 2 or residue 116 in FIG. 5, more preferablycomprises at least about 25 additional amino acids of respectively NCE1or NCE2, even more preferably at least about 50 additional amino acidsof respectively NCE1 or NCE2, still more preferably at least about 75additional amino acids of respectively NCE1 or NCE2, yet even morepreferably at least about 100 additional amino acids of respectivelyNCE1 or NCE2, most preferably at least about 150 additional amino acidsfrom respectively NCE1 or NCE2.

The purified protein and its structural information provided hereinenables the preparation of NCE1 and NCE2 binding molecules, respectivelyNCE1BMs and NCE2BMs. Thus, in a twenty second aspect, the inventionprovides methods for identifying NCE1BMs and NCE2BMs. One preferredmethod according to this aspect of the invention comprises screening forNCE1BMs or NCE2BMs by contacting purified NCE1 or NCE2 according to theinvention and populations or molecules or mixed populations of moleculesand determining the presence of molecules which bind specifically toNCE1 or NCE2. Another preferred method according to this aspect of theinvention comprises rationally designing molecules to bind NCE1 or NCE2based upon structural information from the purified NCE1 or NCE2provided by the invention and determining whether such rationallydesigned molecules bind specifically to NCE1 or NCE2. Molecules thatbind specifically to NCE1 or NCE2 are molecules that bind to NCE1 orNCE2 with greater affinity than to other unrelated proteins. Preferably,binding affinity of the molecule is at least 5-fold greater thanaffinity for unrelated proteins, more preferably at least 10-foldgreater, still more preferably at least 50-fold greater, and mostpreferably at least 100-fold greater. This aspect of the inventionincludes NCE1BMs or NCE2BMs identified by the methods according to theinvention.

As used herein, a “NCE1 or NCE2-binding molecule”, or “NCE1BM orNCE2BM”, is a molecule or macromolecule which binds under physiologicalconditions to, respectively NCE1 or NCE2. The terms “binds underphysiological conditions”, “population of molecules” and “mixedpopulation of molecules” are as used previously.

In certain preferred embodiments, an NCE1BM or NCE2BM according to theinvention is a peptide or a peptidomimetic. For purposes of theinvention, the term “peptide” is as used previously.

In certain preferred embodiments, such as NCE1BM or NCE2BM comprises acomplementarity determining region of an antibody which binds underphysiological conditions to a peptide-containing epitope of,respectively NCE1 or NCE2, or a peptidomimetic of such a complementaritydetermining region. For purposes of the invention, the term“complementarity determining region of an antibody” is as usedpreviously. Accordingly, all such antibody derivatives andpeptidomimetics thereof are contemplated to be within the scope of thepresent invention. Compositions according to the invention may furtherinclude physiologically acceptable diluents, stabilizing agents,localizing agents or buffers.

Additional preferred NCE1BMs and NCE2BMs according to the inventioninclude small molecules, which can be identified using screening orrational design approaches as discussed later herein.

NCE1BMs and NCE2BMs can be used in conventional assays to detect thepresence or absence, and/or quantity of NCE1, or NCE2, or NCE1 orNCE2/NEDD8 complex in a biological sample. Thus, in a twenty-thirdaspect, the invention provides methods of determining the presence orabsence and/or quantity of NCE1 or NCE2, or NCE1 or NCE2/NEDD8 complexin a biological sample. Such methods comprise providing a detectableNCE1BM or NCE2BM to a biological sample, allowing the detectable NCE1BMor NCE2BM to bind to NCE1, or NCE1 or NCE2/NEDD8 complex, if any ispresent in the biological sample, and detecting the presence or absenceand/or quantity of a complex of the detectable NCE1BM or NCE2BM and,respectively, NCE1 or NCE2, or NCE1 or NCE2/NEDD8 complex.

A detectable NCE1BM or NCE2BM is an NCE1BM or NCE2BM which can bedetected in an assay. Such detection is preferably through the direct orindirect binding of a tag or label on the NCE1BM or NCE2BM. The term“direct or indirect binding” is as used previously. Preferred tags andlabels include, without limitation, radiostopes, heavy metals,fluorescent labels, chemoluminescent labels, enzymes and enzymesubstrates. Preferred biological samples include blood, serum, plasma,cells, tissue portions, and cell or tissue extracts. In certainpreferred embodiments, the method according to this aspect of theinvention takes the form of a conventional ELISA or RIA. In anotherpreferred embodiment, the method employs either direct or indirectimmunofluorescence. Additional preferred embodiments utilize in vivoimaging of cells expressing NCE1 or NCE2 using conventional imagingagents directly or indirectly bound to an NCE1BM or NCE2BM according tothe invention.

Nucleic acid sequences specifically complementary to and/or specificallyhomologous to nucleic acid sequences encoding NCE1 or NCE2 can also beused in conventional assays to detect the presence or absence of NCE1 orNCE2 nucleic acid in a biological sample. Thus, in a twenty-fourthaspect, the invention provides methods for determining the presence orabsence and/or quantity of NCE1 or NCE2 nucleic acid in a biologicalsample. In preferred embodiments, such assays are nucleic acidhybridization and/or amplification assays, such assays comprisingproviding to the biological sample a nucleic acid sequence which isspecifically complementary to NCE1 to NCE2 nucleic acid. Particularlypreferred embodiments include Northern blotting, dot or slot blotting,and polymerase chain reaction.

In a twenty-fifth aspect, the invention provides methods for identifyingmodulating ligands of NCE1 or NCE2. Some NCE1BMs and NCE2BMs are capableof acting as antagonists or agonists of, respectively, NCE1 and NCE2.Thus, the method according to this aspect of the invention comprisesproviding NCE1BMs or NCE2BMs to an assay system for, respectively, NCE1or NCE2 participation in the NEDD8-activation/conjugation pathway, anddetermining whether such NCE1BMs or NCE2BMs interfere with or enhancethe ability of NCE1 or NCE2 to participate in theNEDD8-activation/conjugation pathway. The NCE1BMS or NCE2BMs arepreferably provided as a population of molecules (most preferablyrationally designed molecules), or as a mixed population of molecules,as for example in a screening procedure. This aspect of the inventionincludes antagonists or agonists of NCE1 or NCE2 identified by thismethod according to the invention. Assessment of ability to “interferewith or enhance the ability to participate in theNEDD8-activation/conjugation pathway” can conveniently be carried outusing an in vitro activity system, as later described herein.Preferably, such interference or enhancement results in a reduction ofNEDD8 activation/conjugation of at least 50%, more preferably at least90%, and most preferably, at least 99%, or an increase of NEDD8activation/conjugation of at least 50%, preferably at least 2-fold, morepreferably at least 5-fold, most preferably at least 10-fold.

In a twenty-sixth aspect, the invention provides modulating ligands ofNCE1 or NCE2. Preferred modulating ligands are NCE1BMs or NCE2BMs whichact as antagonists, interfering with the ability of, respectively, NCE1or NCE2 to participate in the NEDD8-activation/conjugation pathway.Other preferred modulating ligands are NCE1BMs or NCE2BMs which act asagonists, enhancing the ability of, respectively NCE1 or NCE2 toparticipate in the NEDD8-activation/conjugation pathway. Preferably,such inhibition or enhancement is specific, i.e., the modulating ligandinterferes with or enhances the ability of NCE1 or NCE2 to participatein the NEDD8 activation/conjugation pathway at a concentration that islower than the concentration of the ligand required to produce another,unrelated biological effect. Preferably, the concentration of the ligandrequired for NEDD8 activation/conjugation modulating activity is atleast 2-fold lower, more preferably at least 5-fold lower, even morepreferably at least 10-fold lower, and most preferably at least 20-foldlower than the concentration required to produce an unrelated biologicaleffect. In certain embodiments, such NCE1BMs or NCE2BMs preferablyinteract with, respectively, NCE1 or NCE2 to inhibit or enhance theformation of a thiol ester bond between NEDD8 and NCE1 or NCE2, and/ortransfer of NEDD8 to a target protein.

In a twenty-seventh aspect, the invention provides methods formodulating the formation of a thiol ester bond between NEDD8 and NCE1 orNCE2, or transfer of NEDD8 to a target protein. One preferred embodimentof the method according to this aspect of the invention comprisesproviding a modulating ligand of NCE1 or NCE2 or a recombinantexpression unit which expresses NCE1 or NCE2 or an antagonist thereof toa biological system in which NEDD8 is conjugated to another protein. Theterm “biological system”, as used herein, includes in vitro cell ortissue extracts, cell cultures, tissue cultures, organ cultures, livingplants and animals, including mammals, including without limitationhumans and mice.

In twenty-eighth aspect, the invention provides oligonucleotides thatare specifically complementary to a portion of a nucleotide sequenceshown in FIG. 2 or FIG. 5. For purposes of the invention, the term“oligonucleotide” is as used previously. Certain embodiments of sucholigonucleotides are useful as antisense probes. Other embodiments areuseful as antisense oligonucleotides for use in animal model or humantherapeutic settings.

In a twenty-ninth aspect the invention provides a purified complex ofNCE1 and NEDD8, or of NCE2 and NEDD8. The terms “complex” and “purified”are as used previously.

The following examples are intended to further illustrate certainparticularly preferred embodiments of the invention and are not intendedto limit the scope of the invention. Searches of the human EST databaseutilized the program BLAST (Altschul et al., Nucleic Acid Res 25:3389-3402 (1997)). Searches for transmembrane helices used the programAntheprot V.3.0 Gilbert Deleague, Institute de Biologie et Chemie desProteines 69 367 Lyon cdex 07, France.

EXAMPLE 1 Preparation of Human NEDD8

Nucleotide sequence coding the N-terminal 76 residues of human Nedd8 wasobtained from a human leukocyte cDNA Library (Life TechnologiesTech-Line^(SM), Inc) by nested polymerase chain reaction, using 5′-ccgtgt gca gcc cca aac tgg and 5′-aca ggg taa aga ggt aaa atg as the firstround forward and reverse primer, respectively. In the second round,5′-ggg aat tcc ata tgc taa tta aag tga aga cgc and 5′-cc aag ctt tca tcctcc tct cag agc caa cac were used as the forward and reverse primer,respectively. The second PCR product was digested with Nde1 and HindIIIand ligated to the large fragment of a similarly digested PT7-7 vector.The construct was transformed into the E. coli strain BL21(DE3)/pLysS(Novagen). Nedd8 expression was induced by the addition of 0.5 mM IPTG.The S100 fraction of bacterial extracts was applied to a Q-Sepharosecolumn in 50 mM HEPES, pH 7.5 and the flow-through which contained Nedd8was collected, concentrated by ultrafiltration and fractionated by sizeexclusion chromatography on Superdex G75.

EXAMPLE 2 Identification of NEDD8-Activating Enzyme

To identify the human Nedd8-activating enzyme, we first tested for thepresence of this enzyme activity by monitoring the incorporation ofNedd8 in the form of a thioester linkage into proteins derived from Helacells. On the basis of the chromatographic behavior of recombinant humanNedd8, we generated from Hela cell extracts two protein fractions (FIand FII) which are expected to be devoid of endogenous Nedd8 as follows.To remove Nedd8, 400 mg of protein from Hela cell S100 fraction wasapplied to a 70 ml Q-Sepharose column, equilibrated with 50 mM HEPES, pH8.0 with 1 mM DTT. Proteins in the flow-through fraction wereprecipitated in 90% ammonium sulfate, dialyzed and fractionated by sizeexclusion chromatography on Superdex G75. Fractions which eluted earlierthan Nedd8 were pooled and concentrated by ultrafiltration to 15mg/mland is designated here as FI. Proteins retained by the O-Sepharose wereeluted by inclusion of 0.6 M NaCl in the equilibration buffer. Thecollected proteins were precipitated with 90% ammonium sulfate anddialyzed against 25 mM Hepes, pH7.5, and 1 mM DTT and concentrated to 15mg/ml of protein. This fraction is designated here as FII. Fraction IIwas generated by collecting proteins that were retained by ananion-exchange gel (Q-Sepharose) while FI was obtained by furtherfractionation of unretained proteins by gel filtration. Incubation of¹²⁵I-Nedd8 with FII, but not with FI, produced a radiolabeled band onSDS-gel which migrated at 59 kDa. Formation of this radiolabeled speciesrequired the presence of ATP, and this species could not be detectedwhen DTT was included in the SDS-gel sample buffer. Thus, FII containsan activity which attaches Nedd8 to a protein via a DTT-sensitivelinkage. Incubation of ¹²⁵I-Nedd8 with FI and FII together resulted inthe formation of two additional radiolabeled bands on SDS-gel, migratingat 30 and 97 kDa. Only the 30 kDa species exhibited DTT sensitivity. Oneinterpretation of this result is the presence of a Nedd8-conjugatingenzyme in FI which serves to accept Nedd8 from its activating enzyme inFII to form a 30 kDa thioester.

EXAMPLE 3 Purification of NEDD8-Activating Enzyme

To purify the protein in FII which forms the DTT-sensitive linkage toNedd8, we immobilized Nedd8 to CH-Sepharose 4B gels and used DTT toelute protein that were initially retained by the gel matrix, asfollows. Nedd8-affinity gel was prepared by coupling purified Nedd8 toactivated CH Sepharose 4B (Pharmacia) according to manufacturer'sinstructions and lead to the coupling of 5 mg of Nedd8/ml of gel beads.100 mg of FII protein in a 9 ml reaction buffer containing MgATP and anATP regenerating system was applied to 1 ml of Nedd8-immobilized gelbeads at room temperature. The column was washed sequentially with 5 bedvolumes of buffer A (50 mM Tris-HCl buffer, pH 7.5), buffer A with 0.5MNaCl, and buffer A. A buffer containing 50 mM Tris-HCl, pH 9.0 and 10 mMDTT was used to elute bound proteins. Analysis of the eluted proteins bySDS-PAGE and silver-staining revealed the presence of two major proteinsthat migrated at 60 and 49 kDa. A third major protein, migrating at 43kDa, eluted as a broad peak. When the eluted proteins were analyzed bygel filtration chromatography, the 43 kDa protein eluted as a largeaggregate at the void volume while p60 and p49 were found to co-elutewith a retention time similar to that of the 110 kDaubiquitin-activating enzyme, suggesting that these two proteins form aheterodimer. To determine which one of these two proteins forms theDTT-sensitive linkage with Nedd8, proteins purified from theNedd8-affinity chromatography step were tested. The result is consistentwith p49 being the Nedd8 acceptor. This protein is quantitatively absentonly when ATP or AMPPNP was included in the reaction and only if theelectrophoresis was carried out in the absence of DTT. The fact that nonew discrete protein band was detected under conditions in which p49 wasabsent is likely due to the presence of p60 which precludes thedetection of proteins that would migrate with similar mobility. In aseparate experiment, the use of ¹²⁵I-Nedd8 in the reaction led to thedetection of a DTT-sensitive 59 kDa band, confirming the presence of aNedd8-containing thioester. The ability of AMPPNP to substitute for ATPsuggests that NEDD8 activation, similar to ubiquitin and SUMO-1,involves the intermediate formation of an enzyme-bound Nedd8-adenylateprior to thioester linkage.

EXAMPLE 4 Sequence Determination of NEDD8-Activating Enzyme

To obtain the identity of p49, this protein was excised from an SDS-gel,digested with trypsin and peptides were eluted and purified by HPLC asfollows. The peak fractions form Nedd8-affinity chromatography step wereconcentrated and separated by SDS-PAGE, stained with Coomassie BrilliantBlue, and bands corresponding to p49 and p60 were excised. The gelslices were digested with trypsin, peptides were extracted and purifiedby microbore reversed-phase HPLC (PE-Applied Biosystems model 140A/1000Ssystem) on Zorbax SB-C18 silica columns (1×150 mm). using lineargradients of acetonitrile in 0.08% aqueous trifluoroacetic acid (TFA),essentially as described in (J. Pohl et al, FEBS Lett. 272, 200, 1990.).The masses of the peptides were determined by matrix-assisted laserdesorption ionization mass spectrometry (MALDI-TOF) using a BrukerInstruments model ProFlex MALDI-TOF instrument operated in thereflection mode; 2,5-dihydroxybenzoic acid was used as the samplematrix. The sequences of the peptides were determined by automated Edmandegradation on a PE-Applied Biosystems model Procise HT sequencer systemoperated in the pulsed-liquid mode using manufacturer's suppliedsequencing cycles. Two tryptic peptide sequences are determined (shownas underlined in FIG. 1), and these sequences were used to search theprotein as well as the expressed sequence tag (EST) data bases. Althoughthese sequences did not match known proteins in the data bases, twogroups of EST clones could be identified whose translated amino acidsequence yielded perfect matches to either one of the two trypticpeptides. Further homology search with these EST sequences identifiedadditional EST clones with overlapping sequences. Analysis of these ESTclones enabled us to obtain a contiguous open reading frame (ORF) thatencodes a 442-residue protein which contains the two tryptic peptidesequences. The nucleotide sequence of this ORF was confirmed by directnucleotide sequencing of two EST clones (AA40862 and R57021). Analysisof this protein sequence revealed three regions of homology with humanUba1. Region I contains the putative ATP binding site found in Uba1which is also present in yeast Uba2, and region II contains the PXCTsequence motif found in Uba1 in which the cysteine residue wasidentified by mutational analysis to form thiolester linkage withubiquitin. These similarities are expected if the activation of Nedd8utilizes a mechanism similar to that of ubiquitin and Smt3. Since p49forms a heterodimer with p60 and functions as a protein component ofNedd8 activation, we designate it as Nae_(-beta) and p60 as Nae_(-alpha)Searches of the data banks with this protein sequence identified an openreading frame in S. pombe, and one in C. elegan which code for similarsize proteins. In addition, a S. cerevisiae 299-residue protein, despiteits smaller size, also shows extensive homology with this human protein.These are likely homologues of Nae_(-beta) in different species sinceidentical and highly conserved residues among these four proteins areinterspersed throughout most of the protein whereas their homology toUba1 and Uba2 is limited to defined regions only.

EXAMPLE 5 Identification of Nae-alpha

The similarity between Nedd8- and Smt3-activating enzyme in theirsubunit structure suggested that p60 or Nae_(-alpha) would also containa sequence stretch that shares homology to the N-terminal portion ofUba1. Using procedures similar to those with p49, three tryptic peptidesequences (SEQ ID NOS.: 26-28) were obtained for p60. These sequencesFTVVATQLPEXTXL, EHFQSYDLDHME, and QTPSFWILA yielded perfect matches toresidues 123-138, 194-205 and 300-308 in the 534-residue APP-BP1. Inaddition mass spectrometry of 15 of the tryptic peptides revealedmatches within 1 Da of the expected mass of tryptic peptides of APP-BP1.These matches covered 37% of the APP-BP1 sequence. Thus, we concludedthat Nae_(-alpha) is indeed APP-BP1.

EXAMPLE 6 Identification and Cloning of NCE1

The putative human homology of yeast Ubc12 was identified by searchingthe human EST database for clones having coding sequences that arehomologous to the yeast protein. An initial search using the yeastprotein sequence identified several clones. Clone AA261836, whichcontains a coding sequence very similar to a region of the yeast proteinwas used to search for further EST clones. The search led to theconstruction of a contiguous consensus sequence from overlapping cloneswhich predicts a gene to encode a protein having 183 amino acids, with apredicted molecular mass of 20899 Da. The contiguous nucleotide sequencewas obtained using nested PCR on a human leukocyte cDNA library. Thefirst PCR used primers having the sequences (SEQ ID NOS.: 29 and 30)GCAGGATGATCAAGCTGTTCTCGC (forward) and CGTGGCGGGGGTGGGTATGCGCCA(reversed). The second PCR used the primers (SEQ ID NOS.: 31 and 32)CGGGAATTCCATATGATCAAGCTGTTCTCGCTG (forward) andCGCCCAAGCTTCTATTTCAGGCAGCGCTCAAAG (reversed). The PCR product wasdigested with Nde1 and HindIII and ligated with similarly digestedplasmid pT7-7. The resulting clone, pT7-7-UbcH12, was sequenced todetermine the nucleotide sequence (SEQ ID NO 3) and deduced amino acidsequence (SEQ ID NO 4) shown in FIG. 1. FIG. 2 shows the alignment ofNCE1 with yeast Ubc12. NCE1 shows 41% identity and 63% homology withyeast Ubc12.

EXAMPLE 7 Expression and Purification of NCE1

BL21 (DE3) bacterial cells (Nowagen, Madison, Wis.; catalog no. 69450-1)were transformed with pT7-7-UbcH12 plasmid using conventionalprocedures. The transformed bacteria were induced to express the NCE1protein by adding, to a final concentration of 1 mM,isopropyl-b-D-thiogalactopyranoside (IPTG) to an exponentially growingculture. The culture was allowed to grow for an additional 3 hours at37° C. NCE1 protein was purified from lysed cells by sequential anionexchange and size exclusion chromatography. For anion exchangechromatography, the bacterial extract was loaded at a protein/gel ratioof 15 mg protein/ml gel onto Q-Sepharose (Pharmacia, Piscataway, N.J.)equilibrated with 50 mM HEPES (pH 7.8) and 1 mM DTT. NCE1 protein wasretained by the gel and eluted using a linear NaCl gradient in the gelequilibration buffer. Fractions containing NCE1 protein were determinedby assaying for NEDD8 thioester formation. NCE1 was found to elute at0.08 M NaCl. Active fractions were pooled and concentrated bymicrofiltration and then subjected to size exclusion chromatography onSuperdex-75 (Pharmacia) using a column buffer of 50 mM HEPES (pH 7.8), 1mM DTT and 50 mM NaCl. Fractions were assayed for NEDD8-thioesterformation. NCE1 eluted at a volume expected for a 19 kDa protein,suggesting that it exists as a monomer. SDS-PAGE analysis with Coomassiestain indicated that the preparation was predominantly (>90%) NCE1protein. Purified NCE1 protein migrated on an 8% TRICINE gel at amolecular weight of 21 kDa (data not shown). Extending the N-terminus ofNCE1 with the amino acid sequence (SEQ ID NO.: 33) MHHHHHH resulted inan NCE1 variant protein that retained activity in NEDD8-thioesterformation. The six histidine residues provide a nickel binding site andallowed this variant to be purified with Ni-NTA or other metal affinitychromatography procedures.

EXAMPLE 8 Thioester Formation Between NCE1 and NEDD8

Proteins (as indicated below) were incubated in a reaction buffercontaining 25 mM Hepes (pH7.0), 10 mM Mg²⁺ and 1 mM ATP for 5 minutes at30° C. The reaction was stopped by addition of SDS sample loadingbuffer. Each sample was divided into two aliquots, to one of which wasadded DTT to a final concentration of 10 mM. The DTT-containing samplewas heated in a 95° C. bath for two minutes. Samples were separated on10% SDS-Tricine PAGE, followed by silver staining. The results are shownin FIG. 4. Lanes 1-4 are reaction mixtures 1-4. Lanes 5-8 are reactionmixtures 1-4 which were incubated with 10 mM DTT and heated to 90° C.for two minutes prior to electrophoresis. These results show that NCE1migrates at a slower rate in the presence of NEDD8 and Nae, and thatthis is reversible by DTT. Ubiquitin activating enzyme, E1, cannotsubstitute for NAE in providing this result. These data support the viewthat NCE1 is a NEDD8 conjugating enzyme which forms a thioester withNEDD8 in the presence of activating enzyme, NAE.

Reaction No. Proteins 1 NAE + NEDD8 2 NCE1 + NEDD8 3 NCE1 + NEDD8 + NAE4 NCE1 + NEDD8 + ubiquitin activating enzyme, E1

EXAMPLE 9 Identification and Cloning of NCE2

The human EST database was searched using a query sequence (SEQ ID NO.:34) HPNITETICLSLLREHSIDGTGWA. This is the sequence of clone AA306113 andbears similarity to the active site of proteins in the UBC proteinfamily. Clones were identified which had sequences overlapping thesequence of clone AA306113. The identified sequences of the overlappingEST clones were aligned by the program CLUSTALW (See Thompson et al.,Nucleic Acids Res. 22: 4673-4680 (1994), or by the program SeqMan(DNASTAR, Inc., Madison, Wis.) to yield a consensus sequence, CON1. CON1 was used to perform searches for additional clones with overlappingsequences. The overlapping sequences yielded an open reading frame whichencodes a protein of 185 amino acids (predicted molecular mass=21076Da). Based upon homology to known human Ubc proteins, this gene is amember of the human Ubc gene family. The contiguous nucleotide sequenceof NCE2 was obtained using nested PCR on a human leukocyte cDNA library.The first PCR used the primers (SEQ ID NOS.: 35 and 36)AGCCCAGGGTAAAGGCAGCA (forward) and CATGTTAGAGACAAACTGTA (reversed). Thesecond PCR used the primers (SEQ ID NOS.: 37 and 38)GGGAATTCCATATGCTAACGCTAGCAAGTAA (forward) andCCATCGATTCATCTGGCATAACGTTTGA (reversed). The PCR product was then clonedinto the NdeI/HindIII sites of pT7-7 to generate the plasmidpt7-7-HSUBC17. The sequence of the NCE2 gene and its deduced amino acidsequence are shown in FIG. 4. No close homolog exists in the yeastgenome. The protein has 46% identity and 64% homology with a C. elegansgene (Genebank Accession #CE 275850) of unknown function (see FIG. 5).

EXAMPLE 10 Expression and Purification of NCE2

BL21 (DE3) bacterial cells were transformed with pT7-7-UbcH17 plasmidusing conventional procedures. The transformed bacteria were induced toexpress the NCE2 protein by adding, to a final concentration of 1 mM,isopropyl-b-D-thiogalactopyranoside (IPTG) to an exponentially growingculture. The culture was allowed to grow for an additional 3 hours at37° C. NCE2 protein was purified from lysed cells by sequential anionexchange and size exclusion chromatography. For anion exchangechromatography, the bacterial extract was loaded at a protein/gel ratioof 15 mg protein/ml gel onto Q-Sepharose (Pharmacia) equilibrated with50 mM HEPES (pH 7.8) and 1 mM DTT. NCE2 protein was retained by the geland eluted using a linear NaCl gradient in the gel equilibration buffer.Fractions containing NCE2 protein were determined by assaying for NEDD8thioester formation. NCE2 was found to eluate at 0.8 M NaCl. Activefractions were pooled and concentrated by microfiltration and thensubjected to size exclusion chromatography on Superdex-75 (Pharmacia)using a column buffer of 50 mM HEPES (pH 7.8), 1 mM DTT and 50 mM NaCl.Fractions were assayed for ¹²⁵I-NEDD8-thioester formation. NCE2 elutedat a volume expected for a 21 kDa protein, suggesting that it exists asa monomer. SDS-PAGE analysis with Coomassie stain indicated that thepreparation was predominantly (>90%) NCE2 protein. Purified NCE2 proteinmigrated on an 8% TRICINE gel at a molecular weight of 21 kDa (data notshown).

EXAMPLE 11 Thioester Formation Between NCE2 and NEDD8

The ability of NCE2 to form a thioester bond with NEDD8 was assessed asfollows. NCE2 protein, either purified or from bacterial lysate, wasincubated with ¹²⁵I-NEDD8 (10⁶ cpm/μg) in a buffer containing 25 mMHEPES (pH 7.0), 10 mM MgCl₂, 1 mM ATP and 20 nM purified NAE1 orubiquitin-activating enzyme. The reaction was allowed to proceed at 30°C. for 5 minutes. The reaction was stopped by adding SDS-sample buffereither with or without 10 mM DTT. The samples were subjected to SDS-PAGEand autoradiography. In the reaction containing NCE2 (lane 3), theautoradiograph showed two radiolabelled bands with apparent molecularmasses of 7 and 29 kDa, which are the expected molecular masses of NEDD8and NEDD8-NCE2, respectively. Only the 7 kDa band was detected when thesample was incubated in 10 mM DTT prior to electrophoresis, consistentwith the 29 kDa band being a NEDD8-NCE2 thioester. Analogous reactionscontaining NCE1 in place of NCE2 (lanes 2 and 4) are shown forcomparison. These results demonstrate that NCE2 is capable of forming athioester bond with NEDD8, but not with ubiquitin, in a NAE-dependentreaction. These data support the view that NCE2 is a NEDD8 conjugatingenzyme.

EXAMPLE 12 Preparation of Dominant Negative Mutants

The active site cysteine of a cloned NCE1 or NCE2 is assigned byexamining the sequence alignment with known Ubc proteins (see FIG. 6 foralignment). The active site cysteine is replaced by a serine usingstandard site-specific mutagenesis. The mutant protein is expressed inbacteria and purified. The ability of the mutant protein to form astable oxygen ester with NEDD8 is established as described in Examples 8and 11 above, except that the bond formation is not liable in DTT.Dominant negative mutant activity is then established by introducing themutant protein in increasing concentrations in an assay as described inExamples 8 and 11 above and demonstrating dose-dependent inhibition ofNEDD8/NCE1 or NCE2 complex formation.

38 1 1329 DNA Human misc_feature (1)..(1329) NAE1-beta 1 atg gct gtt gatggt ggg tgt ggg gac act gga gac tgg gaa ggt cgc 48 Met Ala Val Asp GlyGly Cys Gly Asp Thr Gly Asp Trp Glu Gly Arg 1 5 10 15 tgg aac cat gtaaag aag ttc ctc gag cga tct gga ccc ttc aca cac 96 Trp Asn His Val LysLys Phe Leu Glu Arg Ser Gly Pro Phe Thr His 20 25 30 cct gat ttc gaa ccgagc act gaa tct ctc cag ttc ttg tta gat aca 144 Pro Asp Phe Glu Pro SerThr Glu Ser Leu Gln Phe Leu Leu Asp Thr 35 40 45 tgt aaa gtt cta gtc attgga gct ggc ggc tta gga tgt gag ctc ctg 192 Cys Lys Val Leu Val Ile GlyAla Gly Gly Leu Gly Cys Glu Leu Leu 50 55 60 aaa aat ctg gcc ttg tct ggtttt aga cag att cat gtt ata gat atg 240 Lys Asn Leu Ala Leu Ser Gly PheArg Gln Ile His Val Ile Asp Met 65 70 75 80 gac act ata gat gtt tcc aatcta aat agg cag ttt tta ttt agg cct 288 Asp Thr Ile Asp Val Ser Asn LeuAsn Arg Gln Phe Leu Phe Arg Pro 85 90 95 aaa gat att gga aga cct aag gctgaa gtt gct gca gaa ttt cta aat 336 Lys Asp Ile Gly Arg Pro Lys Ala GluVal Ala Ala Glu Phe Leu Asn 100 105 110 gac aga gtt cct aat tgc aat gtagtt cca cat ttc aac aag att caa 384 Asp Arg Val Pro Asn Cys Asn Val ValPro His Phe Asn Lys Ile Gln 115 120 125 gat ttt aac gac act ttc tat cgacaa ttt cat att att gta tgt gga 432 Asp Phe Asn Asp Thr Phe Tyr Arg GlnPhe His Ile Ile Val Cys Gly 130 135 140 ctg gac tct atc atc gcc aga agatgg ata aat ggc atg ctg ata tct 480 Leu Asp Ser Ile Ile Ala Arg Arg TrpIle Asn Gly Met Leu Ile Ser 145 150 155 160 ctt cta aat tat gaa gat ggtgtc tta gat cca agc tcc att gtc cct 528 Leu Leu Asn Tyr Glu Asp Gly ValLeu Asp Pro Ser Ser Ile Val Pro 165 170 175 ttg ata gat ggg ggg aca gaaggt ttt aaa gga aat gcc cgg gtg att 576 Leu Ile Asp Gly Gly Thr Glu GlyPhe Lys Gly Asn Ala Arg Val Ile 180 185 190 ctg cct gga atg act gct tgtatc gaa tgc acg ctg gaa ctt tat cca 624 Leu Pro Gly Met Thr Ala Cys IleGlu Cys Thr Leu Glu Leu Tyr Pro 195 200 205 cca cag gtt aat ttt ccc atgtgc acc att gca tct atg ccc agg cta 672 Pro Gln Val Asn Phe Pro Met CysThr Ile Ala Ser Met Pro Arg Leu 210 215 220 cca gaa cac tgt att gag tatgta agg atg ttg cag tgg cct aag gag 720 Pro Glu His Cys Ile Glu Tyr ValArg Met Leu Gln Trp Pro Lys Glu 225 230 235 240 cag cct ttt gga gaa ggggtt cca tta gat aga gat gat cct gaa cat 768 Gln Pro Phe Gly Glu Gly ValPro Leu Asp Arg Asp Asp Pro Glu His 245 250 255 ata caa tgg att ttc caaaaa tcc cta gag aga gca tca caa tat aat 816 Ile Gln Trp Ile Phe Gln LysSer Leu Glu Arg Ala Ser Gln Tyr Asn 260 265 270 att agg ggt gtt acg tatagg ctc act caa ggg gta gta aaa aga atc 864 Ile Arg Gly Val Thr Tyr ArgLeu Thr Gln Gly Val Val Lys Arg Ile 275 280 285 att cct gca gta gct tccaca aat gca gtc att gca gct gtg tgt gcc 912 Ile Pro Ala Val Ala Ser ThrAsn Ala Val Ile Ala Ala Val Cys Ala 290 295 300 act gag gtt ttt aaa atagcc aca agt gca tac att ccc ttg aat aat 960 Thr Glu Val Phe Lys Ile AlaThr Ser Ala Tyr Ile Pro Leu Asn Asn 305 310 315 320 tac ttg gtg ttt aatgat gta gat ggg ctg tat aca tac aca ttt gaa 1008 Tyr Leu Val Phe Asn AspVal Asp Gly Leu Tyr Thr Tyr Thr Phe Glu 325 330 335 gca gaa aga aag gaaaac tgc cca gct tgt agc cag ctt cct caa aat 1056 Ala Glu Arg Lys Glu AsnCys Pro Ala Cys Ser Gln Leu Pro Gln Asn 340 345 350 att cag ttt tct ccatca gct aaa cta cag gag gtt ttg gat tat cta 1104 Ile Gln Phe Ser Pro SerAla Lys Leu Gln Glu Val Leu Asp Tyr Leu 355 360 365 acc aat agt gct tctctg caa atg aaa tct cca gcc atc aca gcc acc 1152 Thr Asn Ser Ala Ser LeuGln Met Lys Ser Pro Ala Ile Thr Ala Thr 370 375 380 cta gag gga aaa aataga aca ctt tac tta cag tcg gta acc tct att 1200 Leu Glu Gly Lys Asn ArgThr Leu Tyr Leu Gln Ser Val Thr Ser Ile 385 390 395 400 gaa gaa cga acaagg cca aat ctc tcc aaa aca ttg aaa gaa ttg ggg 1248 Glu Glu Arg Thr ArgPro Asn Leu Ser Lys Thr Leu Lys Glu Leu Gly 405 410 415 ctt gtt gat ggacaa gaa ctg gcg gtt gct gat gtc acc acc cca cag 1296 Leu Val Asp Gly GlnGlu Leu Ala Val Ala Asp Val Thr Thr Pro Gln 420 425 430 act gta cta ttcaaa ctt cat ttt act tct taa 1329 Thr Val Leu Phe Lys Leu His Phe Thr Ser435 440 2 442 PRT Human misc_feature (1)..(1329) NAE1-beta 2 Met Ala ValAsp Gly Gly Cys Gly Asp Thr Gly Asp Trp Glu Gly Arg 1 5 10 15 Trp AsnHis Val Lys Lys Phe Leu Glu Arg Ser Gly Pro Phe Thr His 20 25 30 Pro AspPhe Glu Pro Ser Thr Glu Ser Leu Gln Phe Leu Leu Asp Thr 35 40 45 Cys LysVal Leu Val Ile Gly Ala Gly Gly Leu Gly Cys Glu Leu Leu 50 55 60 Lys AsnLeu Ala Leu Ser Gly Phe Arg Gln Ile His Val Ile Asp Met 65 70 75 80 AspThr Ile Asp Val Ser Asn Leu Asn Arg Gln Phe Leu Phe Arg Pro 85 90 95 LysAsp Ile Gly Arg Pro Lys Ala Glu Val Ala Ala Glu Phe Leu Asn 100 105 110Asp Arg Val Pro Asn Cys Asn Val Val Pro His Phe Asn Lys Ile Gln 115 120125 Asp Phe Asn Asp Thr Phe Tyr Arg Gln Phe His Ile Ile Val Cys Gly 130135 140 Leu Asp Ser Ile Ile Ala Arg Arg Trp Ile Asn Gly Met Leu Ile Ser145 150 155 160 Leu Leu Asn Tyr Glu Asp Gly Val Leu Asp Pro Ser Ser IleVal Pro 165 170 175 Leu Ile Asp Gly Gly Thr Glu Gly Phe Lys Gly Asn AlaArg Val Ile 180 185 190 Leu Pro Gly Met Thr Ala Cys Ile Glu Cys Thr LeuGlu Leu Tyr Pro 195 200 205 Pro Gln Val Asn Phe Pro Met Cys Thr Ile AlaSer Met Pro Arg Leu 210 215 220 Pro Glu His Cys Ile Glu Tyr Val Arg MetLeu Gln Trp Pro Lys Glu 225 230 235 240 Gln Pro Phe Gly Glu Gly Val ProLeu Asp Arg Asp Asp Pro Glu His 245 250 255 Ile Gln Trp Ile Phe Gln LysSer Leu Glu Arg Ala Ser Gln Tyr Asn 260 265 270 Ile Arg Gly Val Thr TyrArg Leu Thr Gln Gly Val Val Lys Arg Ile 275 280 285 Ile Pro Ala Val AlaSer Thr Asn Ala Val Ile Ala Ala Val Cys Ala 290 295 300 Thr Glu Val PheLys Ile Ala Thr Ser Ala Tyr Ile Pro Leu Asn Asn 305 310 315 320 Tyr LeuVal Phe Asn Asp Val Asp Gly Leu Tyr Thr Tyr Thr Phe Glu 325 330 335 AlaGlu Arg Lys Glu Asn Cys Pro Ala Cys Ser Gln Leu Pro Gln Asn 340 345 350Ile Gln Phe Ser Pro Ser Ala Lys Leu Gln Glu Val Leu Asp Tyr Leu 355 360365 Thr Asn Ser Ala Ser Leu Gln Met Lys Ser Pro Ala Ile Thr Ala Thr 370375 380 Leu Glu Gly Lys Asn Arg Thr Leu Tyr Leu Gln Ser Val Thr Ser Ile385 390 395 400 Glu Glu Arg Thr Arg Pro Asn Leu Ser Lys Thr Leu Lys GluLeu Gly 405 410 415 Leu Val Asp Gly Gln Glu Leu Ala Val Ala Asp Val ThrThr Pro Gln 420 425 430 Thr Val Leu Phe Lys Leu His Phe Thr Ser 435 4403 552 DNA Human misc_feature (1)..(552) NEDD8-conjugating enzyme 1(NCE1) 3 atg atc aag ctg ttc tcg ctg aag cag cag aag aag gag gag gag tcg48 Met Ile Lys Leu Phe Ser Leu Lys Gln Gln Lys Lys Glu Glu Glu Ser 1 510 15 gcg ggc ggc acc aag ggc agc agc aag aag gcg tcg gcg gcg cag ctg 96Ala Gly Gly Thr Lys Gly Ser Ser Lys Lys Ala Ser Ala Ala Gln Leu 20 25 30cgg atc cag aag gac ata aac gag ctg aac ctg ccc aag acg tgt gat 144 ArgIle Gln Lys Asp Ile Asn Glu Leu Asn Leu Pro Lys Thr Cys Asp 35 40 45 atcagc ttc tca gat cca gac gac ctc ctc aac ttc aag ctg gtc atc 192 Ile SerPhe Ser Asp Pro Asp Asp Leu Leu Asn Phe Lys Leu Val Ile 50 55 60 tgt cctgat gag ggc ttc tac aag agt ggg aag ttt gtg ttc agt ttt 240 Cys Pro AspGlu Gly Phe Tyr Lys Ser Gly Lys Phe Val Phe Ser Phe 65 70 75 80 aag gtgggc cag ggt tac ccg cat gat ccc ccc aag gtg aag tgt gag 288 Lys Val GlyGln Gly Tyr Pro His Asp Pro Pro Lys Val Lys Cys Glu 85 90 95 aca atg gtctat cac ccc aac att gac ctc gag ggc aac gtc tgc ctc 336 Thr Met Val TyrHis Pro Asn Ile Asp Leu Glu Gly Asn Val Cys Leu 100 105 110 aac atc ctcaga gag gac tgg aag cca gtc ctt acg ata aac tcc ata 384 Asn Ile Leu ArgGlu Asp Trp Lys Pro Val Leu Thr Ile Asn Ser Ile 115 120 125 att tat ggcctg cag tat ctc ttc ttg gag ccc aac ccc gag gac cca 432 Ile Tyr Gly LeuGln Tyr Leu Phe Leu Glu Pro Asn Pro Glu Asp Pro 130 135 140 ctg aac aaggag gcc gca gag gtc ctg cag aac aac cgg cgg ctg ttt 480 Leu Asn Lys GluAla Ala Glu Val Leu Gln Asn Asn Arg Arg Leu Phe 145 150 155 160 gag cagaac gtg cag cgc tcc atg cgg ggt ggc tac atc ggc tcc acc 528 Glu Gln AsnVal Gln Arg Ser Met Arg Gly Gly Tyr Ile Gly Ser Thr 165 170 175 tac tttgag cgc tgc ctg aaa tag 552 Tyr Phe Glu Arg Cys Leu Lys 180 4 183 PRTHuman misc_feature (1)..(552) NEDD8-conjugating enzyme 1 (NCE1) 4 MetIle Lys Leu Phe Ser Leu Lys Gln Gln Lys Lys Glu Glu Glu Ser 1 5 10 15Ala Gly Gly Thr Lys Gly Ser Ser Lys Lys Ala Ser Ala Ala Gln Leu 20 25 30Arg Ile Gln Lys Asp Ile Asn Glu Leu Asn Leu Pro Lys Thr Cys Asp 35 40 45Ile Ser Phe Ser Asp Pro Asp Asp Leu Leu Asn Phe Lys Leu Val Ile 50 55 60Cys Pro Asp Glu Gly Phe Tyr Lys Ser Gly Lys Phe Val Phe Ser Phe 65 70 7580 Lys Val Gly Gln Gly Tyr Pro His Asp Pro Pro Lys Val Lys Cys Glu 85 9095 Thr Met Val Tyr His Pro Asn Ile Asp Leu Glu Gly Asn Val Cys Leu 100105 110 Asn Ile Leu Arg Glu Asp Trp Lys Pro Val Leu Thr Ile Asn Ser Ile115 120 125 Ile Tyr Gly Leu Gln Tyr Leu Phe Leu Glu Pro Asn Pro Glu AspPro 130 135 140 Leu Asn Lys Glu Ala Ala Glu Val Leu Gln Asn Asn Arg ArgLeu Phe 145 150 155 160 Glu Gln Asn Val Gln Arg Ser Met Arg Gly Gly TyrIle Gly Ser Thr 165 170 175 Tyr Phe Glu Arg Cys Leu Lys 180 5 558 DNAHuman misc_feature (1)..(558) NEDD8-conjugating enzyme 2 (NCE2) 5 atgcta acg cta gca agt aaa ctg aag cgt gac gat ggt ctc aaa ggg 48 Met LeuThr Leu Ala Ser Lys Leu Lys Arg Asp Asp Gly Leu Lys Gly 1 5 10 15 tcccgg acg gca gcc aca gcg tcc gac tcg act cgg agg gtt tct gtg 96 Ser ArgThr Ala Ala Thr Ala Ser Asp Ser Thr Arg Arg Val Ser Val 20 25 30 aga gacaaa ttg ctt gtt aaa gag gtt gca gaa ctt gaa gct aat tta 144 Arg Asp LysLeu Leu Val Lys Glu Val Ala Glu Leu Glu Ala Asn Leu 35 40 45 cct tgt acatgt aaa gtg cat ttt cct gat cca aac aag ctt cat tgt 192 Pro Cys Thr CysLys Val His Phe Pro Asp Pro Asn Lys Leu His Cys 50 55 60 ttt cag cta acagta acc cca gat gag ggt tac tac cag ggt gga aaa 240 Phe Gln Leu Thr ValThr Pro Asp Glu Gly Tyr Tyr Gln Gly Gly Lys 65 70 75 80 ttt cag ttt gaaact gaa gtt ccc gat gcg tac aac atg gtg cct ccc 288 Phe Gln Phe Glu ThrGlu Val Pro Asp Ala Tyr Asn Met Val Pro Pro 85 90 95 aaa gtg aaa tgc ctgacc aag atc tgg cac ccc aac atc aca gag aca 336 Lys Val Lys Cys Leu ThrLys Ile Trp His Pro Asn Ile Thr Glu Thr 100 105 110 ggg gaa ata tgt ctgagt tta ttg aga gaa cat tca att gat ggc act 384 Gly Glu Ile Cys Leu SerLeu Leu Arg Glu His Ser Ile Asp Gly Thr 115 120 125 ggc tgg gct ccc acaaga aca tta aag gat gtc gtt tgg gga tta aac 432 Gly Trp Ala Pro Thr ArgThr Leu Lys Asp Val Val Trp Gly Leu Asn 130 135 140 tct ttg ttt act gatctt ttg aat ttt gat gat cca ctg aat att gaa 480 Ser Leu Phe Thr Asp LeuLeu Asn Phe Asp Asp Pro Leu Asn Ile Glu 145 150 155 160 gct gca gaa catcat ttg cgg gac aag gag gac ttc cgg aat aaa gtg 528 Ala Ala Glu His HisLeu Arg Asp Lys Glu Asp Phe Arg Asn Lys Val 165 170 175 gat gac tac atcaaa cgt tat gcc aga tga 558 Asp Asp Tyr Ile Lys Arg Tyr Ala Arg 180 1856 185 PRT Human misc_feature (1)..(558) NEDD8-conjugating enzyme 2(NCE2) 6 Met Leu Thr Leu Ala Ser Lys Leu Lys Arg Asp Asp Gly Leu Lys Gly1 5 10 15 Ser Arg Thr Ala Ala Thr Ala Ser Asp Ser Thr Arg Arg Val SerVal 20 25 30 Arg Asp Lys Leu Leu Val Lys Glu Val Ala Glu Leu Glu Ala AsnLeu 35 40 45 Pro Cys Thr Cys Lys Val His Phe Pro Asp Pro Asn Lys Leu HisCys 50 55 60 Phe Gln Leu Thr Val Thr Pro Asp Glu Gly Tyr Tyr Gln Gly GlyLys 65 70 75 80 Phe Gln Phe Glu Thr Glu Val Pro Asp Ala Tyr Asn Met ValPro Pro 85 90 95 Lys Val Lys Cys Leu Thr Lys Ile Trp His Pro Asn Ile ThrGlu Thr 100 105 110 Gly Glu Ile Cys Leu Ser Leu Leu Arg Glu His Ser IleAsp Gly Thr 115 120 125 Gly Trp Ala Pro Thr Arg Thr Leu Lys Asp Val ValTrp Gly Leu Asn 130 135 140 Ser Leu Phe Thr Asp Leu Leu Asn Phe Asp AspPro Leu Asn Ile Glu 145 150 155 160 Ala Ala Glu His His Leu Arg Asp LysGlu Asp Phe Arg Asn Lys Val 165 170 175 Asp Asp Tyr Ile Lys Arg Tyr AlaArg 180 185 7 552 DNA Human misc_feature (1)..(552) NEDD8-conjugatingenzyme 1 (NCE1) 7 tactagttcg acaagagcga cttcgtcgtc ttcttcctcc tcctcagccgcccgccgtgg 60 ttcccgtcgt cgttcttccg cagccgccgc gtcgacgcct aggtcttcctgtatttgctc 120 gacttggacg ggttctgcac actatagtcg aagagtctag gtctgctggaggagttgaag 180 ttcgaccagt agacaggact actcccgaag atgttctcac ccttcaaacacaagtcaaaa 240 ttccacccgg tcccaatggg cgtactaggg gggttccact tcacactctgttaccagata 300 gtggggttgt aactggagct cccgttgcag acggagttgt aggagtctctcctgaccttc 360 ggtcaggaat gctatttgag gtattaaata ccggacgtca tagagaagaacctcgggttg 420 gggctcctgg gtgacttgtt cctccggcgt ctccaggacg tcttgttggccgccgacaaa 480 ctcgtcttgc acgtcgcgag gtacgcccca ccgatgtagc cgaggtggatgaaactcgcg 540 acggacttta tc 552 8 140 PRT Yeast MISC_FEATURE (1)..(188)Yeast Ubc12 8 Met Leu Lys Leu Arg Gln Leu Gln Lys Lys Lys Gln Lys GluAsn Glu 1 5 10 15 Asn Ser Ser Ser Ile Gln Pro Asn Leu Ser Ala Ala ArgIle Arg Leu 20 25 30 Lys Arg Asp Leu Asp Ser Leu Asp Leu Pro Pro Thr ValThr Leu Asn 35 40 45 Val Ile Thr Ser Pro Asp Ser Ala Asp Arg Ser Gln SerPro Lys Leu 50 55 60 Asn Val Cys Leu Asn Ile Leu Arg Glu Asp Trp Ser ProAla Leu Asp 65 70 75 80 Leu Gln Ser Ile Ile Thr Gly Leu Leu Phe Leu PheLeu Glu Pro Asn 85 90 95 Pro Asn Asp Pro Leu Asn Lys Asp Ala Ala Lys LeuLeu Cys Glu Gly 100 105 110 Glu Lys Glu Phe Ala Glu Ala Val Arg Leu ThrMet Ser Gly Gly Ser 115 120 125 Ile Glu His Val Lys Tyr Asp Asn Ile ValSer Pro 130 135 140 9 558 DNA Human misc_feature (1)..(558)NEDD-conjugating enzyme 2 (NCE2) 9 tacgattgcg atcgttcatt tgacttcgcactgctaccag agtttcccag ggcctgccgt 60 cggtgtcgca ggctgagctg agcctcccaaagacactctc tgtttaacga acaatttctc 120 caacgtcttg aacttcgatt aaatggaacatgtacatttc acgtaaaagg actaggtttg 180 ttcgaagtaa caaaagtcga ttgtcattggggtctactcc caatgatggt cccacctttt 240 aaagtcaaac tttgacttca agggctacgcatgttgtacc acggagggtt tcactttacg 300 gactggttct agaccgtggg gttgtagtgtctctgtcccc tttatacaga ctcaaataac 360 tctcttgtaa gttaactacc gtgaccgacccgagggtgtt cttgtaattt cctacagcaa 420 acccctaatt tgagaaacaa atgactagaaaacttaaaac tactaggtga cttataactt 480 cgacgtcttg tagtaaacgc cctgttcctcctgaaggcct tatttcacct actgatgtag 540 tttgcaatac ggtctact 558 10 180 PRTCaenorhabditis elegans MISC_FEATURE (1)..(180) Ce275850 10 Met Phe AsnLeu Gln Lys Arg Ile Asn Gly Asn Asn Glu Asp Gly Arg 1 5 10 15 Tyr LeuGlu Thr Arg Ile Ala Val Arg Asp Lys Leu Leu Ala Gln Glu 20 25 30 Leu GlnGln Leu Glu Thr Ala Leu Arg Asp Gln Lys Gln Lys Leu Trp 35 40 45 His LeuGlu Val Pro Ser Thr Ser Cys Leu His Glu Leu Glu Leu Thr 50 55 60 Val ThrPro Gln Glu Gly Ile Tyr Arg Gly Gly Lys Phe Arg Phe Lys 65 70 75 80 IleThr Val Pro Pro Glu Tyr Asn Asn Val Pro Pro Val Val Lys Cys 85 90 95 LeuThr Lys Val Trp His Pro Asn Ile Asn Glu Asp Gly Ser Ile Cys 100 105 110Leu Ser Ile Leu Arg Gln Asn Ser Leu Asp Gln Tyr Gly Trp Arg Pro 115 120125 Thr Arg Asn Leu Thr Asp Val Val His Gly Leu Val Ser Leu Phe Asn 130135 140 Asp Leu Met Asp Phe Asn Asp Ala Leu Asn Ile Gln Ala Ala Gln Met145 150 155 160 Trp Ser Trp Asn Arg Glu Ser Phe Asn His Arg Val Arg GluTyr Ile 165 170 175 Ser Arg Tyr Cys 180 11 200 PRT Yeast MISC_FEATURE(1)..(200) UBC1 11 Met Ala Asn Ile Ala Val Gln Arg Ile Lys Arg Glu PheLys Glu Val 1 5 10 15 Leu Lys Ser Glu Glu Thr Ser Lys Asn Gln Ile LysVal Asp Leu Val 20 25 30 Asp Glu Asn Phe Thr Glu Leu Arg Gly Glu Ile AlaGly Pro Pro Asp 35 40 45 Thr Pro Tyr Glu Gly Gly Arg Tyr Gln Leu Glu IleLys Ile Pro Glu 50 55 60 Thr Tyr Pro Phe Asn Pro Pro Lys Val Arg Phe IleThr Lys Ile Trp 65 70 75 80 His Pro Asn Ile Ser Ser Val Thr Gly Ala IleCys Leu Asp Leu Leu 85 90 95 Lys Asp Gln Trp Ala Ala Ala Met Thr Leu ArgThr Val Leu Leu Ser 100 105 110 Leu Gln Ala Asp Leu Ala Ala Ala Glu ProAsp Asp Pro Gln Asp Ala 115 120 125 Val Val Ala Asn Gln Tyr Lys Gln AsnPro Glu Met Phe Lys Gln Thr 130 135 140 Ala Arg Leu Trp Ala His Val TyrAla Gly Ala Pro Val Ser Ser Pro 145 150 155 160 Glu Tyr Thr Lys Lys IleGlu Asn Leu Cys Ala Met Gly Phe Asp Arg 165 170 175 Asn Ala Val Ile ValAla Leu Ser Ser Lys Ser Trp Asp Val Glu Thr 180 185 190 Ala Thr Glu LeuLeu Leu Ser Asn 195 200 12 152 PRT Human MISC_FEATURE (1)..(152) UBC2b12 Met Ser Thr Pro Ala Arg Arg Arg Leu Met Arg Asp Phe Lys Arg Leu 1 510 15 Gln Glu Asp Pro Pro Val Gly Val Ser Gly Ala Pro Ser Glu Asn Asn 2025 30 Ile Met Gln Trp Asn Ala Val Ile Phe Gly Pro Glu Gly Thr Pro Phe 3540 45 Glu Asp Gly Thr Phe Lys Leu Val Ile Glu Phe Ser Glu Glu Tyr Pro 5055 60 Asn Lys Pro Pro Thr Val Arg Phe Val Ser Lys Met Phe His Pro Asn 6570 75 80 Val Tyr Ala Asp Gly Ser Ile Cys Leu Asp Ile Leu Gln Asn Arg Trp85 90 95 Ser Pro Thr Tyr Asp Val Ser Ser Ile Leu Thr Ser Ile Gln Ser Asp100 105 110 Leu Asp Glu Pro Asn Pro Asn Ser Pro Ala Asn Ser Gln Ala AlaGln 115 120 125 Leu Tyr Gln Glu Asn Lys Arg Glu Tyr Glu Lys Arg Val SerAla Ile 130 135 140 Val Ile Gln Ser Trp Asn Asp Ser 145 150 13 152 PRTHuman MISC_FEATURE (1)..(152) UBC2a 13 Met Ser Thr Pro Ala Arg Arg ArgLeu Met Arg Asp Phe Lys Arg Leu 1 5 10 15 Gln Glu Asp Pro Pro Ala GlyVal Ser Gly Ala Pro Ser Glu Asn Asn 20 25 30 Ile Met Val Trp Asn Ala ValIle Phe Gly Pro Glu Gly Thr Pro Phe 35 40 45 Gly Asp Gly Thr Phe Lys LeuThr Ile Glu Phe Thr Glu Glu Tyr Pro 50 55 60 Asn Lys Pro Pro Thr Val ArgPhe Val Ser Lys Met Phe His Pro Asn 65 70 75 80 Val Tyr Ala Asp Gly SerIle Cys Leu Asp Ile Leu Gln Asn Arg Trp 85 90 95 Ser Pro Thr Tyr Asp ValSer Ser Ile Leu Thr Ser Ile Gln Ser Asp 100 105 110 Leu Asp Glu Pro AsnPro Asn Ser Pro Ala Asn Ser Gln Ala Ala Gln 115 120 125 Leu Tyr Gln GluAsn Lys Arg Glu Tyr Glu Lys Arg Val Ser Ala Ile 130 135 140 Val Ile GlnSer Trp Arg Asp Cys 145 150 14 236 PRT Human MISC_FEATURE (1)..(236)Cdc34a 14 Met Ala Arg Pro Leu Val Pro Ser Ser Gln Lys Ala Leu Leu LeuGlu 1 5 10 15 Leu Lys Gly Leu Gln Glu Glu Pro Val Glu Gly Phe Arg ValThr Leu 20 25 30 Val Asp Glu Gly Asp Leu Tyr Asn Trp Glu Val Ala Ile PheGly Pro 35 40 45 Pro Asn Thr Tyr Tyr Glu Gly Gly Tyr Phe Lys Ala Arg LeuLys Phe 50 55 60 Pro Ile Asp Tyr Pro Tyr Ser Pro Pro Ala Phe Arg Phe LeuThr Lys 65 70 75 80 Met Trp His Pro Asn Ile Tyr Glu Thr Gly Asp Val CysIle Ser Ile 85 90 95 Leu His Pro Pro Val Asp Asp Pro Gln Ser Gly Glu LeuPro Ser Glu 100 105 110 Arg Trp Asn Pro Thr Gln Asn Val Arg Thr Ile LeuLeu Ser Val Ile 115 120 125 Ser Asp Leu Asn Glu Pro Asn Thr Phe Ser ProAla Asn Val Asp Ala 130 135 140 Ser Val Met Tyr Arg Lys Trp Lys Glu SerLys Gly Lys Asp Arg Glu 145 150 155 160 Tyr Thr Asp Ile Ile Arg Lys GlnVal Leu Gly Thr Lys Val Asp Ala 165 170 175 Glu Arg Asp Gly Val Lys ValPro Thr Thr Leu Ala Glu Tyr Cys Val 180 185 190 Lys Thr Lys Ala Pro AlaPro Asp Glu Gly Ser Asp Leu Phe Tyr Asp 195 200 205 Asp Tyr Tyr Glu AspGly Glu Val Glu Glu Glu Ala Asp Ser Cys Phe 210 215 220 Gly Asp Asp GluAsp Asp Ser Gly Thr Glu Glu Ser 225 230 235 15 147 PRT HumanMISC_FEATURE (1)..(147) UBC5b 15 Met Ala Leu Lys Arg Ile His Lys Glu LeuAsn Asp Leu Ala Arg Asp 1 5 10 15 Pro Pro Ala Gln Cys Ser Ala Gly ProVal Gly Asp Asp Met Phe His 20 25 30 Trp Gln Ala Thr Ile Met Gly Pro AsnAsp Ser Pro Tyr Gln Gly Gly 35 40 45 Val Phe Phe Leu Thr Ile His Phe ProThr Asp Tyr Pro Phe Lys Pro 50 55 60 Pro Lys Val Ala Phe Thr Thr Arg IleTyr His Pro Asn Ile Asn Ser 65 70 75 80 Asn Gly Ser Ile Cys Leu Asp IleLeu Arg Ser Gln Trp Ser Pro Ala 85 90 95 Leu Thr Ile Ser Lys Val Leu LeuSer Ile Cys Ser Asp Leu Cys Asp 100 105 110 Pro Asn Pro Asp Asp Pro LeuVal Pro Glu Ile Ala Arg Ile Tyr Lys 115 120 125 Thr Asp Arg Glu Lys TyrAsn Arg Ile Ala Arg Glu Trp Thr Gln Lys 130 135 140 Tyr Ala Met 145 16147 PRT Human MISC_FEATURE (1)..(147) UBC5c 16 Met Ala Leu Lys Arg IleAsn Lys Glu Leu Ser Asp Leu Ala Arg Asp 1 5 10 15 Pro Pro Ala Gln CysSer Ala Gly Pro Val Gly Asp Asp Met Phe His 20 25 30 Trp Gln Ala Thr IleMet Gly Pro Asn Asp Ser Pro Tyr Gln Gly Gly 35 40 45 Val Phe Phe Leu ThrIle His Phe Pro Thr Asp Tyr Pro Phe Lys Pro 50 55 60 Pro Lys Val Ala PheThr Thr Arg Ile Tyr His Pro Asn Ile Asn Ser 65 70 75 80 Asn Gly Ser IleCys Leu Asp Ile Leu Arg Ser Gln Trp Ser Pro Ala 85 90 95 Leu Thr Ile SerLys Val Leu Leu Ser Ile Cys Ser Asp Leu Cys Asp 100 105 110 Pro Asn ProAsp Asp Pro Leu Val Pro Glu Ile Ala Arg Ile Tyr Lys 115 120 125 Thr AspArg Asp Lys Tyr Asn Arg Ile Ser Arg Glu Trp Thr Gln Lys 130 135 140 TyrAla Met 145 17 147 PRT Human MISC_FEATURE (1)..(147) UBC5a 17 Met AlaLeu Lys Arg Ile Gln Lys Glu Leu Ser Asp Leu Gln Arg Asp 1 5 10 15 ProPro Ala His Cys Ser Ala Gly Pro Val Gly Asp Asp Leu Phe His 20 25 30 TrpGln Ala Thr Ile Met Gly Pro Pro Asp Ser Ala Tyr Gln Gly Gly 35 40 45 ValPhe Phe Leu Thr Val His Phe Pro Thr Asp Tyr Pro Phe Lys Pro 50 55 60 ProLys Ile Ala Phe Thr Thr Lys Ile Tyr His Pro Asn Ile Asn Ser 65 70 75 80Asn Gly Ser Ile Cys Leu Asp Ile Leu Arg Ser Gln Trp Ser Pro Ala 85 90 95Leu Thr Val Ser Lys Val Leu Leu Ser Ile Cys Ser Asp Leu Thr Asp 100 105110 Cys Asn Pro Asp Asp Pro Leu Val Pro Asp Ile Ala Gln Ile Tyr Lys 115120 125 Ser Asp Lys Glu Lys Tyr Asn Arg His Ala Arg Glu Trp Thr Gln Lys130 135 140 Tyr Ala Met 145 18 193 PRT Human MISC_FEATURE (1)..(193)UbcH6 18 Met Ser Asp Asp Asp Ser Arg Ala Ser Thr Ser Ser Ser Ser Ser Ser1 5 10 15 Ser Ser Asn Gln Gln Thr Glu Lys Glu Thr Asn Thr Pro Lys LysLys 20 25 30 Glu Ser Lys Val Ser Met Ser Lys Asn Ser Lys Leu Leu Ser ThrSer 35 40 45 Ala Lys Arg Ile Gln Lys Glu Leu Ala Asp Ile Thr Leu Asp ProPro 50 55 60 Pro Asn Cys Ser Ala Gly Pro Lys Gly Asp Asn Ile Tyr Glu TrpArg 65 70 75 80 Ser Thr Ile Leu Gly Pro Pro Gly Ser Val Tyr Glu Gly GlyVal Phe 85 90 95 Phe Leu Asp Ile Thr Phe Thr Pro Glu Tyr Pro Phe Lys ProPro Lys 100 105 110 Val Thr Phe Arg Thr Arg Ile Tyr His Cys Asn Ile AsnSer Gln Gly 115 120 125 Val Ile Cys Leu Asp Ile Leu Lys Asp Asn Trp SerPro Ala Leu Thr 130 135 140 Ile Ser Lys Val Leu Leu Ser Ile Cys Ser AspLeu Thr Asp Cys Asn 145 150 155 160 Pro Ala Asp Pro Leu Val Gly Ser IleAla Thr Gln Tyr Met Thr Asn 165 170 175 Arg Ala Glu His Asp Arg Met AlaArg Gln Trp Thr Lys Arg Tyr Ala 180 185 190 Thr 19 154 PRT HumanMISC_FEATURE (1)..(154) UbcH7 19 Met Ala Ala Ser Arg Arg Leu Met Lys GluLeu Glu Glu Ile Arg Lys 1 5 10 15 Cys Gly Met Lys Asn Phe Arg Asn IleGln Val Asp Glu Ala Asn Leu 20 25 30 Leu Thr Trp Gln Gly Leu Ile Val ProAsp Asn Pro Pro Tyr Asp Lys 35 40 45 Gly Ala Phe Arg Ile Glu Ile Asn PhePro Ala Glu Tyr Pro Phe Lys 50 55 60 Pro Pro Lys Ile Thr Phe Lys Thr LysIle Tyr His Pro Asn Ile Asp 65 70 75 80 Glu Lys Gly Gln Val Cys Leu ProVal Ile Ser Ala Glu Asn Trp Lys 85 90 95 Pro Ala Thr Lys Thr Asp Gln ValIle Gln Ser Leu Ile Ala Asp Val 100 105 110 Asn Asp Pro Gln Pro Glu HisPro Leu Arg Ala Asp Leu Ala Glu Glu 115 120 125 Tyr Ser Lys Asp Arg LysLys Phe Cys Lys Asn Ala Glu Glu Phe Thr 130 135 140 Lys Lys Tyr Gly GluLys Arg Pro Val Asp 145 150 20 152 PRT Human MISC_FEATURE (1)..(152)UbcH8 20 Met Ala Ser Met Arg Val Val Lys Glu Leu Glu Asp Leu Gln Lys Lys1 5 10 15 Pro Pro Pro Tyr Leu Arg Asn Leu Ser Ser Asp Asp Ala Asn ValLeu 20 25 30 Val Trp His Ala Leu Leu Leu Pro Asp Gln Pro Pro Tyr His LeuLys 35 40 45 Ala Phe Asn Leu Arg Ile Ser Phe Pro Pro Glu Tyr Pro Phe LysPro 50 55 60 Pro Met Ile Lys Phe Thr Thr Lys Ile Tyr His Pro Asn Val AspGlu 65 70 75 80 Asn Gly Gln Ile Cys Leu Pro Ile Ile Ser Ser Glu Asn TrpLys Pro 85 90 95 Cys Thr Lys Thr Cys Gln Val Leu Glu Ala Leu Asn Val AspVal Asn 100 105 110 Arg Pro Asn Ile Arg Glu Pro Leu Arg Met Asp Leu AlaAsp Leu Leu 115 120 125 Thr Gln Asn Pro Glu Leu Phe Arg Lys Asn Ala GluGlu Phe Thr Leu 130 135 140 Arg Phe Gly Val Asp Arg Pro Ser 145 150 21170 PRT Human MISC_FEATURE (1)..(170) UBE2G 21 Met Thr Glu Leu Gln SerAla Leu Leu Leu Arg Arg Gln Leu Ala Glu 1 5 10 15 Leu Asn Lys Asn ProVal Glu Gly Phe Ser Ala Gly Leu Ile Asp Asp 20 25 30 Asn Asp Leu Tyr ArgTrp Glu Val Leu Ile Ile Gly Pro Pro Asp Thr 35 40 45 Leu Tyr Glu Gly GlyVal Phe Lys Ala His Leu Thr Phe Pro Lys Asp 50 55 60 Tyr Pro Leu Arg ProPro Lys Met Lys Phe Ile Thr Glu Ile Trp His 65 70 75 80 Pro Asn Val AspLys Asn Gly Asp Val Cys Ile Ser Ile Leu His Glu 85 90 95 Pro Gly Glu AspLys Tyr Gly Tyr Glu Lys Pro Glu Glu Arg Trp Leu 100 105 110 Pro Ile HisThr Val Glu Thr Ile Met Ile Ser Val Ile Ser Met Leu 115 120 125 Ala AspPro Asn Gly Asp Ser Pro Ala Asn Val Asp Ala Ala Lys Glu 130 135 140 TrpArg Glu Asp Arg Asn Gly Glu Phe Lys Arg Lys Val Ala Arg Cys 145 150 155160 Val Arg Lys Ser Gln Glu Thr Ala Phe Glu 165 170 22 183 PRT HumanMISC_FEATURE (1)..(183) UBCH(8) 22 Met Ser Ser Pro Ser Pro Gly Lys ArgArg Met Asp Thr Asp Val Val 1 5 10 15 Lys Leu Ile Glu Ser Lys His GluVal Thr Ile Leu Gly Gly Leu Asn 20 25 30 Glu Phe Val Val Lys Phe Tyr GlyPro Gln Gly Thr Pro Tyr Glu Gly 35 40 45 Gly Val Trp Lys Val Arg Val AspLeu Pro Asp Lys Tyr Pro Phe Lys 50 55 60 Ser Pro Ser Ile Gly Phe Met AsnLys Ile Phe His Pro Asn Ile Asp 65 70 75 80 Glu Ala Ser Gly Thr Val CysLeu Asp Val Ile Asn Gln Thr Trp Thr 85 90 95 Ala Leu Tyr Asp Leu Thr AsnIle Phe Glu Ser Phe Leu Pro Gln Leu 100 105 110 Leu Ala Tyr Pro Asn ProIle Asp Pro Leu Asn Gly Asp Ala Ala Ala 115 120 125 Met Tyr Leu His ArgPro Glu Glu Tyr Lys Gln Lys Ile Lys Glu Tyr 130 135 140 Ile Gln Lys TyrAla Thr Glu Glu Ala Leu Lys Glu Gln Glu Glu Gly 145 150 155 160 Thr GlyAsp Ser Ser Ser Glu Ser Ser Met Ser Asp Phe Ser Glu Asp 165 170 175 GluAla Gln Asp Met Glu Leu 180 23 158 PRT Human MISC_FEATURE (1)..(158)UBC9 23 Met Ser Gly Ile Ala Leu Ser Arg Leu Ala Gln Glu Arg Lys Ala Trp1 5 10 15 Arg Lys Asp His Pro Phe Gly Phe Val Ala Val Pro Thr Lys AsnPro 20 25 30 Asp Gly Thr Met Asn Leu Met Asn Trp Glu Cys Ala Ile Pro GlyLys 35 40 45 Lys Gly Thr Pro Trp Glu Gly Gly Leu Phe Lys Leu Arg Met LeuPhe 50 55 60 Lys Asp Asp Tyr Pro Ser Ser Pro Pro Lys Cys Lys Phe Glu ProPro 65 70 75 80 Leu Phe His Pro Asn Val Tyr Pro Ser Gly Thr Val Cys LeuSer Ile 85 90 95 Leu Glu Glu Asp Lys Asp Trp Arg Pro Ala Ile Thr Ile LysGln Ile 100 105 110 Leu Leu Gly Ile Gln Glu Asp Leu Asn Glu Pro Asn IleGln Asp Pro 115 120 125 Ala Gln Ala Glu Ala Tyr Thr Ile Tyr Cys Gln AsnArg Val Glu Tyr 130 135 140 Glu Lys Arg Val Arg Ala Gln Ala Lys Lys PheAla Pro Ser 145 150 155 24 180 PRT Human MISC_FEATURE (1)..(180) UBCH1024 Met Ala Ser Gln Asn Arg Asp Pro Ala Ala Thr Ser Val Ala Ala Ala 1 510 15 Ala Arg Lys Gly Ala Glu Pro Ser Gly Gly Ala Ala Arg Gly Pro Val 2025 30 Gly Lys Arg Leu Gln Gln Glu Leu Met Thr Leu Met Met Ser Gly Asp 3540 45 Lys Gly Ile Ser Ala Phe Pro Glu Ser Asp Asn Leu Phe Lys Trp Val 5055 60 Gly Thr Ile His Gly Ala Ala Gly Thr Val Tyr Glu Asp Leu Arg Tyr 6570 75 80 Lys Leu Ser Leu Glu Phe Pro Ser Gly Tyr Pro Tyr Asn Ala Pro Thr85 90 95 Val Lys Phe Leu Thr Pro Cys Tyr His Pro Asn Val Asp Thr Gln Gly100 105 110 Asn Ile Cys Leu Asp Ile Leu Lys Glu Lys Trp Ser Ala Leu TyrAsp 115 120 125 Val Arg Thr Ile Leu Leu Ser Ile Gln Ser Asp Leu Gly GluPro Asn 130 135 140 Ile Asp Ser Pro Leu Asn Thr His Ala Ala Glu Leu TrpLys Asn Pro 145 150 155 160 Thr Ala Phe Lys Lys Tyr Leu Gln Glu Thr TyrSer Lys Gln Val Thr 165 170 175 Ser Gln Glu Pro 180 25 152 PRT HumanMISC_FEATURE (1)..(152) UBC 13 25 Met Ala Gly Leu Pro Arg Arg Ile IleLys Glu Thr Gln Arg Leu Leu 1 5 10 15 Ala Glu Pro Val Pro Gly Ile LysAla Glu Pro Asp Glu Ser Asn Ala 20 25 30 Arg Tyr Phe His Val Val Ile AlaGly Pro Gln Asp Ser Pro Phe Glu 35 40 45 Gly Gly Thr Phe Lys Leu Glu LeuPhe Leu Pro Glu Glu Tyr Pro Met 50 55 60 Ala Ala Pro Lys Val Arg Phe MetThr Lys Ile Tyr His Pro Asn Val 65 70 75 80 Asp Lys Leu Gly Arg Ile CysLeu Asp Ile Leu Lys Asp Glu Trp Ser 85 90 95 Pro Ala Leu Gln Ile Arg ThrVal Leu Leu Ser Ile Gln Ala Asp Leu 100 105 110 Ser Ala Pro Asn Pro AspAsp Pro Leu Ala Asn Asp Val Ala Glu Gln 115 120 125 Trp Lys Thr Asn GluAla Gln Ala Ile Glu Thr Ala Arg Ala Trp Thr 130 135 140 Arg Leu Tyr AlaMet Asn Asn Ile 145 150 26 14 PRT Artificial Sequence Tryptic peptidesequence for p60 26 Phe Thr Val Val Ala Thr Gln Leu Pro Glu Xaa Thr XaaLeu 1 5 10 27 12 PRT Artificial Sequence Tryptic peptide sequence forp60 27 Glu His Phe Gln Ser Tyr Asp Leu Asp His Met Glu 1 5 10 28 9 PRTArtificial Sequence Tryptic peptide sequence for p60 28 Gln Thr Pro SerPhe Trp Ile Leu Ala 1 5 29 24 DNA Human 29 gcaggatgat caagctgttc tcgc 2430 24 DNA Human 30 cgtggcgggg gtgggtatgc gcca 24 31 33 DNA Human 31cgggaattcc atatgatcaa gctgttctcg ctg 33 32 33 DNA Human 32 cgcccaagcttctatttcag gcagcgctca aag 33 33 7 PRT Artificial Sequence N-terminus ofNCE1 33 Met His His His His His His 1 5 34 24 PRT Human 34 His Pro AsnIle Thr Glu Thr Ile Cys Leu Ser Leu Leu Arg Glu His 1 5 10 15 Ser IleAsp Gly Thr Gly Trp Ala 20 35 20 DNA Human 35 agcccagggt aaaggcagca 2036 20 DNA Human 36 catgttagag acaaactgta 20 37 31 DNA Human 37gggaattcca tatgctaacg ctagcaagta a 31 38 28 DNA Human 38 ccatcgattcatctggcata acgtttga 28

What is claimed is:
 1. A purified NEDD8-activating protein beta subunit(NAE1-beta), comprising an amino acid sequence set forth in SEQ ID NO:2, wherein the subunit has the activity of forming a thioester linkagewith NEDD8.
 2. An NAE1-beta expression element that is an isolated orrecombinant nucleic acid sequence encoding NAE1-beta comprising of SEQID NO: 2 and having NAE1-beta biological activity comprising forming athioester linkage with NEDD8.
 3. A method for identifying NAE1BBMscomprising contacting purified NAE1-beta according to claim 1 withpopulations of molecules or mixed populations of molecules anddetermining the presence of molecules which bind specifically toNAE1-beta.
 4. A method for determining the presence or absence and/orquantity of NAE1-beta nucleic acid in a biological sample comprising: a)hybridizing a nucleic acid sequence which is specifically complementaryto SEQ ID NO: 1 to a biological sample, thereby forming a hybridizationcomplex; and b) detecting said hybridization complex, wherein thepresence of said hybridization complex indicates the presence of NAE-1beta nucleic acid.
 5. An NAE1-beta expression element that is anisolated or recombinant nucleic acid sequence comprising the nucleicacid sequence set forth in SEQ ID NO: 1, wherein the expression elementhas NAE1-beta biological activity comprising forming a thioester linkagewith NEDD8.
 6. An NAE1-beta expression element that is an isolated orrecombinant nucleic acid sequence encoding NAE1-beta comprising of SEQID NO: 2 with the cysteine residue at position 216 replaced with serineand having activity as a dominant negative mutant thereof, wherein thedominant negative mutant inhibits the ability of NAE1 to form athioester linkage with NEDD8 or to transfer NEDD8 to a NEDD8 conjugatingenzyme.
 7. An NAE1-beta expression element that is a vector orrecombinant expression unit comprising the nucleic acid sequence ofclaim
 5. 8. An NAE1-beta expression element that is a vector recombinantexpression unit comprising the nucleic acid sequence of claim 2 or 6.